174 results on '"Myocardial Infarction"'
Search Results
2. THE INCIDENCE OF ARRHYTHMIAS IN ACUTE MYOCARDIAL INFARCTION STUDIES WITH A CONSTANT MONITORING SYSTEM.
- Author
-
KURLAND GS and PRESSMAN D
- Subjects
- Incidence, Anterior Wall Myocardial Infarction, Arrhythmias, Cardiac, Electrocardiography, Geriatrics, Mortality, Myocardial Infarction, Statistics as Topic
- Published
- 1965
- Full Text
- View/download PDF
3. Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort.
- Author
-
Miles, Jeremy, Scotti, Andrea, Castagna, Francesco, Toshiki Kuno, Leone, Pier Pasquale, Coisne, Augustin, Ludwig, Sebastian, Lavie, Carl J., Joshi, Parag H., Latib, Azeem, Garcia, Mario J., Rodriguez, Carlos J., Shapiro, Michael D., Virani, Salim S., and Slipczuk, Leandro
- Subjects
- *
LDL cholesterol , *HDL cholesterol , *MYOCARDIAL infarction , *HEART failure , *HYPERCHOLESTEREMIA , *BODY mass index , *RACE - Abstract
BACKGROUND:Tools for mortality prediction in patients with the severe hypercholesterolemia phenotype (low-density lipoprotein cholesterol ≥190 mg/dL) are limited and restricted to specific racial and ethnic cohorts. We sought to evaluate the predictors of long-term mortality in a large racially and ethnically diverse US patient cohort with low-density lipoprotein cholesterol ≥190 mg/dL.METHODS:We conducted a retrospective analysis of all patients with a low-density lipoprotein cholesterol ≥190 mg/dL seeking care at Montefiore from 2010 through 2020. Patients <18 years of age or with previous malignancy were excluded. The primary end point was all-cause mortality. Analyses were stratified by age, sex, and race and ethnicity. Patients were stratified by primary and secondary prevention. Cox regression analyses were used to adjust for demographic, clinical, and treatment variables.RESULTS:A total of 18 740 patients were included (37% non-Hispanic Black, 30% Hispanic, 12% non-Hispanic White, and 2% non-Hispanic Asian patients). The mean age was 53.9 years, and median follow-up was 5.2 years. Both high-density lipoprotein cholesterol and body mass index extremes were associated with higher mortality in univariate analyses. In adjusted models, higher low-density lipoprotein cholesterol and triglyceride levels were associated with an increased 9-year mortality risk (adjusted hazard ratio [HR], 1.08 [95% CI, 1.05–1.11] and 1.04 [95% CI, 1.02–1.06] per 20–mg/dL increase, respectively). Clinical factors associated with higher mortality included male sex (adjusted HR, 1.31 [95% CI, 1.08–1.58]), older age (adjusted HR, 1.19 per 5-year increase [95% CI, 1.15–1.23]), hypertension (adjusted HR, 2.01 [95% CI, 1.57–2.57]), chronic kidney disease (adjusted HR, 1.68 [95% CI, 1.36–2.09]), diabetes (adjusted HR, 1.79 [95% CI, 1.50–2.15]), heart failure (adjusted HR, 1.51 [95% CI, 1.16–1.95]), myocardial infarction (adjusted HR, 1.41 [95% CI, 1.05–1.90]), and body mass index <20 kg/m² (adjusted HR, 3.36 [95% CI, 2.29–4.93]). A significant survival benefit was conferred by lipid-lowering therapy (adjusted HR, 0.57 [95% CI, 0.42–0.77]). In the primary prevention group, high-density lipoprotein cholesterol <40 mg/dL was independently associated with higher mortality (adjusted HR, 1.49 [95% CI, 1.06–2.09]). Temporal trend analyses showed a reduction in statin use over time (P<0.001). In the most recent time period (2019–2020), 56% of patients on primary prevention and 85% of those on secondary prevention were on statin therapy.CONCLUSIONS:In a large, diverse cohort of US patients with the severe hypercholesterolemia phenotype, we identified several patient characteristics associated with increased 9-year all-cause mortality and observed a decrease in statin use over time, in particular for primary prevention. Our results support efforts geared toward early recognition and consistent treatment for patients with severe hypercholesterolemia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.
- Author
-
Ridker, Paul M., Lei, Lei, Louie, Michael J., Haddad, Tariq, Nicholls, Stephen J., Lincoff, A. Michael, Libby, Peter, and Nissen, Steven E.
- Subjects
- *
MYOCARDIAL infarction , *LDL cholesterol , *DYSLIPIDEMIA , *CHOLESTEROL , *STATINS (Cardiovascular agents) , *MORTALITY ,CARDIOVASCULAR disease related mortality - Abstract
BACKGROUND: Among patients treated with statin therapy to guideline-recommended cholesterol levels, residual inflammatory risk assessed by high-sensitivity C-reactive protein (hsCRP) is at least as strong a predictor of future cardiovascular events as is residual risk assessed by low-density lipoprotein cholesterol (LDLC). Whether these relationships are present among statin-intolerant patients with higher LDLC levels is uncertain but has implications for the choice of preventive therapies, including bempedoic acid, an agent that reduces both LDLC and hsCRP. METHODS: The multinational CLEAR-Outcomes trial (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen Outcomes Trial) randomly allocated 13 970 statin-intolerant patients to 180 mg of oral bempedoic acid daily or matching placebo and followed them for a 4-component composite of incident myocardial infarction, stroke, coronary revascularization, or cardiovascular death, and for all-cause mortality. Quartiles of increasing baseline hsCRP and LDLC were assessed as predictors of future adverse events after adjustment for traditional risk factors and randomized treatment assignment. RESULTS: Compared with placebo, bempedoic acid reduced median hsCRP by 21.6% and mean LDLC levels by 21.1% at 6 months. Baseline hsCRP was significantly associated with the primary composite end point of major cardiovascular events (highest versus lowest hsCRP quartile; hazard ratio [HR], 1.43 [95% CI, 1.24-1.65]), cardiovascular mortality (HR, 2.00 [95% CI, 1.53-2.61]), and all-cause mortality (HR, 2.21 [95% CI, 1.79-2.73]). By contrast, the relationship of baseline LDLC quartile (highest versus lowest) to future events was smaller in magnitude for the primary composite cardiovascular end point (HR, 1.19 [95% CI, 1.04-1.37]) and neutral for cardiovascular mortality (HR, 0.90 [95% CI, 0.70-1.17]) and all-cause mortality (HR, 0.95 [95% CI, 0.78-1.16]). Risks were high for those with elevated hsCRP irrespective of LDLC level. Bempedoic acid demonstrated similar efficacy in reducing cardiovascular events across all levels of hsCRP and LDLC. CONCLUSIONS: Among contemporary statin-intolerant patients, inflammation assessed by hsCRP predicted risk for future cardiovascular events and death more strongly than hyperlipidemia assessed by LDLC. Compared with placebo, bempedoic acid had similar efficacy for reducing cardiovascular risk across hsCRP and LDLC strata. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Graft Failure After Coronary Artery Bypass Grafting and Its Association With Patient Characteristics and Clinical Events: A Pooled Individual Patient Data Analysis of Clinical Trials With Imaging Follow-Up.
- Author
-
Gaudino, Mario, Sandner, Sigrid, An, Kevin R., Dimagli, Arnaldo, Di Franco, Antonino, Audisio, Katia, Harik, Lamia, Perezgrovas-Olaria, Roberto, Soletti, Giovanni, Fremes, Stephen E., Hare, David L., Kulik, Alexander, Lamy, Andre, Peper, Joyce, Ruel, Marc, ten Berg, Jurrien M., Willemsen, Laura M., Qiang Zhao, Wojdyla, Daniel M., and Bhatt, Deepak L.
- Subjects
- *
CORONARY artery bypass , *MYOCARDIAL infarction , *DIAGNOSTIC imaging , *CLINICAL trials , *DATA analysis , *ARTERIAL grafts - Abstract
BACKGROUND: Graft patency is the postulated mechanism for the benefits of coronary artery bypass grafting (CABG). However, systematic graft imaging assessment after CABG is rare, and there is a lack of contemporary data on the factors associated with graft failure and on the association between graft failure and clinical events after CABG. METHODS: We pooled individual patient data from randomized clinical trials with systematic CABG graft imaging to assess the incidence of graft failure and its association with clinical risk factors. The primary outcome was the composite of myocardial infarction or repeat revascularization occurring after CABG and before imaging. A 2-stage meta-analytic approach was used to evaluate the association between graft failure and the primary outcome. We also assessed the association between graft failure and myocardial infarction, repeat revascularization, or all-cause death occurring after imaging. RESULTS: Seven trials were included comprising 4413 patients (mean age, 64.4±9.1 years; 777 [17.6%] women; 3636 [82.4%] men) and 13 163 grafts (8740 saphenous vein grafts and 4423 arterial grafts). The median time to imaging was 1.02 years (interquartile range [IQR], 1.00-1.03). Graft failure occurred in 1487 (33.7%) patients and in 2190 (16.6%) grafts. Age (adjusted odds ratio [aOR], 1.08 [per 10-year increment] [95% CI, 1.01-1.15]; P=0.03), female sex (aOR, 1.27 [95% CI, 1.08-1.50]; P=0.004), and smoking (aOR, 1.20 [95% CI, 1.04-1.38]; P=0.01) were independently associated with graft failure, whereas statins were associated with a protective effect (aOR, 0.74 [95% CI, 0.63-0.88]; P<0.001). Graft failure was associated with an increased risk of myocardial infarction or repeat revascularization occurring between CABG and imaging assessment (8.0% in patients with graft failure versus 1.7% in patients without graft failure; aOR, 3.98 [95% CI, 3.54-4.47]; P<0.001). Graft failure was also associated with an increased risk of myocardial infarction or repeat revascularization occurring after imaging (7.8% versus 2.0%; aOR, 2.59 [95% CI, 1.86-3.62]; P<0.001). All-cause death after imaging occurred more frequently in patients with graft failure compared with patients without graft failure (11.0% versus 2.1%; aOR, 2.79 [95% CI, 2.01-3.89]; P<0.001). CONCLUSIONS: In contemporary practice, graft failure remains common among patients undergoing CABG and is strongly associated with adverse cardiac events. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.
- Author
-
Bikdeli, Behnood, Erlinge, David, Valgimigli, Marco, Kastrati, Adnan, Yaling Han, Steg, Philippe Gabriel, Stables, Rod H., Mehran, Roxana, James, Stefan K., Frigoli, Enrico, Goldstein, Patrick, Yi Li, Shahzad, Adeel, Schüpke, Stefanie, Mehdipoor, Ghazaleh, Chen, Shmuel, Redfors, Björn, Crowley, Aaron, Zhipeng Zhou, and Stone, Gregg W.
- Subjects
- *
ST elevation myocardial infarction , *HEPARIN , *BIVALIRUDIN , *NON-ST elevated myocardial infarction , *MYOCARDIAL infarction - Abstract
BACKGROUND: The benefit:risk profile of bivalirudin versus heparin anticoagulation in patients with non--ST-segment--elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) is uncertain. Study-level meta-analyses lack granularity to provide conclusive answers. We sought to compare the outcomes of bivalirudin and heparin in patients with non--ST-segment--elevation myocardial infarction undergoing PCI. METHODS: We performed an individual patient data meta-analysis of patients with non--ST-segment--elevation myocardial infarction in all 5 trials that randomized ≥1000 patients with any myocardial infarction undergoing PCI to bivalirudin versus heparin (MATRIX [Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox], VALIDATE-SWEDEHEART [Bivalirudin Versus Heparin in ST-Segment and Non--ST-Segment Elevation Myocardial Infarction in Patients on Modern Antiplatelet Therapy in the Swedish Web System for Enhancement and Development of Evidence- Based Care in Heart Disease Evaluated According to Recommended Therapies Registry Trial], ISAR-REACT 4 [Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 4], ACUITY [Acute Catheterization and Urgent Intervention Triage Strategy], and BRIGHT [Bivalirudin in Acute Myocardial Infarction vs Heparin and GPI Plus Heparin Trial]). The primary effectiveness and safety end points were 30-day all-cause mortality and serious bleeding. RESULTS: A total of 12 155 patients were randomized: 6040 to bivalirudin (52.3% with a post-PCI bivalirudin infusion), and 6115 to heparin (53.2% with planned glycoprotein IIb/IIIa inhibitor use). Thirty-day mortality was not significantly different between bivalirudin and heparin (1.2% versus 1.1%; adjusted odds ratio, 1.24 [95% CI, 0.86--1.79]; P=0.25). Cardiac mortality, reinfarction, and stent thrombosis rates were also not significantly different. Bivalirudin reduced serious bleeding (both access site--related and non--access site--related) compared with heparin (3.3% versus 5.5%; adjusted odds ratio, 0.59; 95% CI, 0.48--0.72; P<0.0001). Outcomes were consistent regardless of use of a post-PCI bivalirudin infusion or routine lycoprotein IIb/IIIa inhibitor use with heparin and during 1-year follow-up. CONCLUSIONS: In patients with non--ST-segment--elevation myocardial infarction undergoing PCI, procedural anticoagulation with bivalirudin and heparin did not result in significantly different rates of mortality or ischemic events, including stent thrombosis and reinfarction. Bivalirudin reduced serious bleeding compared with heparin arising both from the access site and nonaccess sites. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Existing Nongated CT Coronary Calcium Predicts Operative Risk in Patients Undergoing Noncardiac Surgeries (ENCORES).
- Author
-
Choi, Daniel Y., Hayes, Dena, Maidman, Samuel D., Dhaduk, Nehal, Jacobs, Jill E., Shmukler, Anna, Berger, Jeffrey S., Cuff, Germaine, Rehe, David, Lee, Mitchell, Donnino, Robert, and Smilowitz, Nathaniel R.
- Subjects
- *
CORONARY artery calcification , *COMPUTED tomography , *CALCIUM , *MYOCARDIAL perfusion imaging , *MYOCARDIAL infarction , *CORONARY arteries - Abstract
BACKGROUND: Preoperative cardiovascular risk stratification before noncardiac surgery is a common clinical challenge. Coronary artery calcium scores from ECG-gated chest computed tomography (CT) imaging are associated with perioperative events. At the time of preoperative evaluation, many patients will not have had ECG-gated CT imaging, but will have had nongated chest CT studies performed for a variety of noncardiac indications. We evaluated relationships between coronary calcium severity estimated from previous nongated chest CT imaging and perioperative major clinical events (MCE) after noncardiac surgery. METHODS: We retrospectively identified consecutive adults age ≥45 years who underwent in-hospital, major noncardiac surgery from 2016 to 2020 at a large academic health system composed of 4 acute care centers. All patients had nongated (contrast or noncontrast) chest CT imaging performed within 1 year before surgery. Coronary calcium in each vessel was retrospectively graded from absent to severe using a 0 to 3 scale (absent, mild, moderate, severe) by physicians blinded to clinical data. The estimated coronary calcium burden (ECCB) was computed as the sum of scores for each coronary artery (0 to 9 scale). A Revised Cardiac Risk Index was calculated for each patient. Perioperative MCE was defined as all-cause death or myocardial infarction within 30 days of surgery. RESULTS: A total of 2554 patients (median age, 68 years; 49.7% women; median Revised Cardiac Risk Index, 1) were included. The median time interval from nongated chest CT imaging to noncardiac surgery was 15 days (interquartile range, 3-106 days). The median ECCB was 1 (interquartile range, 0-3). Perioperative MCE occurred in 136 (5.2%) patients. Higher ECCB values were associated with stepwise increases in perioperative MCE (0: 2.9%, 1-2: 3.7%, 3-5: 8.0%; 6-9: 12.6%, P<0.001). Addition of ECCB to a model with the Revised Cardiac Risk Index improved the C-statistic for MCE (from 0.675 to 0.712, P=0.018), with a net reclassification improvement of 0.428 (95% CI, 0.254-0.601, P<0.0001). An ECCB ≥3 was associated with 2-fold higher adjusted odds of MCE versus an ECCB <3 (adjusted odds ratio, 2.11 [95% CI, 1.42-3.12]). CONCLUSIONS: Prevalence and severity of coronary calcium obtained from existing nongated chest CT imaging improve preoperative clinical risk stratification before noncardiac surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Extreme Temperature Events, Fine Particulate Matter, and Myocardial Infarction Mortality.
- Author
-
Ruijun Xu, Suli Huang, Chunxiang Shi, Rui Wang, Tingting Liu, Yingxin Li, Yi Zheng, Ziquan Lv, Jing Wei, Hong Sun, and Yuewei Liu
- Subjects
- *
PARTICULATE matter , *HEAT waves (Meteorology) , *MYOCARDIAL infarction , *OLDER people , *AIR quality , *EARLY death - Abstract
BACKGROUND: Extreme temperature events (ETEs), including heat wave and cold spell, have been linked to myocardial infarction (MI) morbidity; however, their effects on MI mortality are less clear. Although ambient fine particulate matter (PM2.5) is suggested to act synergistically with extreme temperatures on cardiovascular mortality, it remains unknown if and how ETEs and PM2.5 interact to trigger MI deaths. METHODS: A time-stratified case-crossover study of 202 678 MI deaths in Jiangsu province, China, from 2015 to 2020, was conducted to investigate the association of exposure to ETEs and PM2.5 with MI mortality and evaluate their interactive effects. On the basis of ambient apparent temperature, multiple temperature thresholds and durations were used to build 12 ETE definitions. Daily ETEs and PM2.5 exposures were assessed by extracting values from validated grid datasets at each subject's geocoded residential address. Conditional logistic regression models were applied to perform exposure-response analyses and estimate relative excess odds due to interaction, proportion attributable to interaction, and synergy index. RESULTS: Under different ETE definitions, the odds ratio of MI mortality associated with heat wave and cold spell ranged from 1.18 (95% CI, 1.14-1.21) to 1.74 (1.66-1.83), and 1.04 (1.02-1.06) to 1.12 (1.07-1.18), respectively. Lag 01-day exposure to PM2.5 was significantly associated with an increased odds of MI mortality, which attenuated at higher exposures. We observed a significant synergistic interaction of heat wave and PM2.5 on MI mortality (relative excess odds due to interaction >0, proportion attributable to interaction >0, and synergy index >1), which was higher, in general, for heat wave with greater intensities and longer durations. We estimated that up to 2.8% of the MI deaths were attributable to exposure to ETEs and PM2.5 at levels exceeding the interim target 3 value (37.5 µg/m³) of World Health Organization air quality guidelines. Women and older adults were more vulnerable to ETEs and PM2.5. The interactive effects of ETEs or PM2.5 on MI mortality did not vary across sex, age, or socioeconomic status. CONCLUSIONS: This study provides consistent evidence that exposure to both ETEs and PM2.5 is significantly associated with an increased odds of MI mortality, especially for women and older adults, and that heat wave interacts synergistically with PM2.5 to trigger MI deaths but cold spell does not. Our findings suggest that mitigating both ETE and PM2.5 exposures may bring health cobenefits in preventing premature deaths from MI. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Race-Based Differences in ST-Segment–Elevation Myocardial Infarction Process Metrics and Mortality From 2015 Through 2021: An Analysis of 178 062 Patients From the American Heart Association Get With The Guidelines–Coronary Artery Disease Registry
- Author
-
Osho, Asishana, Fernandes, Marcelo F., Poudel, Ram, de Lemos, James, Hong, Haoyun, Zhao, Juan, Li, Shen, Thomas, Kathie, Kikuchi, Daniel S., Zegre-Hemsey, Jessica, Ibrahim, Nasrien, Shah, Nilay S., Hollowell, Lori, Tamis-Holland, Jacqueline, Granger, Christopher B., Cohen, Mauricio, Henry, Timothy, Jacobs, Alice K., Jollis, James G., and Yancy, Clyde W.
- Subjects
- *
MYOCARDIAL infarction , *MEDICAL registries , *ARTERIAL diseases , *HOSPITAL emergency services , *BLACK people , *HISPANIC American women - Abstract
BACKGROUND: Systems of care have been developed across the United States to standardize care processes and improve outcomes in patients with ST-segment–elevation myocardial infarction (STEMI). The effect of contemporary STEMI systems of care on racial and ethnic disparities in achievement of time-to-treatment goals and mortality in STEMI is uncertain. METHODS: We analyzed 178 062 patients with STEMI (52 293 women and 125 769 men) enrolled in the American Heart Association Get With The Guidelines–Coronary Artery Disease registry between January 1, 2015, and December 31, 2021. Patients were stratified into and outcomes compared among 3 racial and ethnic groups: non-Hispanic White, Hispanic White, and Black. The primary outcomes were the proportions of patients achieving the following STEMI process metrics: prehospital ECG obtained by emergency medical services; hospital arrival to ECG obtained within 10 minutes for patients not transported by emergency medical services; arrival-to–percutaneous coronary intervention time within 90 minutes; and first medical contact–to-device time within 90 minutes. A secondary outcome was in-hospital mortality. Analyses were performed separately in women and men, and all outcomes were adjusted for age, comorbidities, acuity of presentation, insurance status, and socioeconomic status measured by social vulnerability index based on patients' county of residence. RESULTS: Compared with non-Hispanic White patients with STEMI, Hispanic White patients and Black patients had lower odds of receiving a prehospital ECG and achieving targets for door-to-ECG, door-to-device, and first medical contact–to-device times. These racial disparities in treatment goals were observed in both women and men, and persisted in most cases after multivariable adjustment. Compared with non-Hispanic White women, Hispanic White women had higher adjusted in-hospital mortality (odds ratio, 1.39 [95% CI, 1.12–1.72]), whereas Black women did not (odds ratio, 0.88 [95% CI, 0.74–1.03]). Compared with non-Hispanic White men, adjusted in-hospital mortality was similar in Hispanic White men (odds ratio, 0.99 [95% CI, 0.82–1.18]) and Black men (odds ratio, 0.96 [95% CI, 0.85–1.09]). CONCLUSIONS: Race- or ethnicity-based disparities persist in STEMI process metrics in both women and men, and mortality differences are observed in Hispanic White compared with non-Hispanic White women. Further research is essential to evolve systems of care to mitigate racial differences in STEMI outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. If the Fates Allow: The Zero-Sum Game of ISCHEMIA-EXTEND.
- Author
-
Bradley, Steven M. and Gluckman, Ty J.
- Subjects
- *
ZERO sum games , *MYOCARDIAL infarction , *MYOCARDIAL ischemia , *CORONARY disease - Abstract
Editorials, ischemia, mortality, myocardial ischemia, coronary angiography Keywords: Editorials; coronary angiography; ischemia; mortality; myocardial ischemia EN Editorials coronary angiography ischemia mortality myocardial ischemia 20 22 3 12/29/22 20230103 NES 230103 B Article, see p 8 b According to the ancient Greeks, the lives of the gods and mortals were immutably determined by 3 Fates: sisters Clotho, who spins the thread of life; Lachesis, who assigns each their destiny; and Atropos, whose scissors snip the thread of life at its end. Analyses from ISCHEMIA,[10] and COURAGE before it,[11] have demonstrated a time-dependent effect of an invasive strategy on patient-reported health status, most notably symptom burden among patients with more severe anginal symptoms at baseline. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
11. Response by Xu et al to Letter Regarding Article, “Extreme Temperature Events, Fine Particulate Matter, and Myocardial Infarction Mortality”.
- Author
-
Ruijun Xu, Suli Huang, Jing Wei, Hong Sun, and Yuewei Liu
- Subjects
- *
MYOCARDIAL infarction , *PARTICULATE matter , *MORTALITY , *TEMPERATURE - Published
- 2024
- Full Text
- View/download PDF
12. Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
- Author
-
Aytekin, Alp, Ndrepepa, Gjin, Neumann, Franz-Josef, Menichelli, Maurizio, Mayer, Katharina, Wöhrle, Jochen, Bernlochner, Isabell, Lahu, Shqipdona, Richardt, Gert, Witzenbichler, Bernhard, Sibbing, Dirk, Cassese, Salvatore, Angiolillo, Dominick J., Valina, Christian, Kufner, Sebastian, Liebetrau, Christoph, Hamm, Christian W., Xhepa, Erion, Hapfelmeier, Alexander, and Sager, Hendrik B.
- Subjects
- *
PERCUTANEOUS coronary intervention , *MYOCARDIAL infarction , *TICAGRELOR , *PRASUGREL , *MEDICAL equipment , *RESEARCH , *STROKE , *TIME , *RESEARCH methodology , *MEDICAL care , *NEUROTRANSMITTERS , *SURGICAL stents , *MEDICAL cooperation , *EVALUATION research , *CARDIOVASCULAR system , *MEDICAL care research , *DISEASE relapse , *TREATMENT effectiveness , *RISK assessment , *COMPARATIVE studies , *RANDOMIZED controlled trials , *DRUGS , *PLATELET aggregation inhibitors , *HEMORRHAGE - Abstract
Background: Data on the comparative efficacy and safety of ticagrelor versus prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention are limited. We assessed the efficacy and safety of ticagrelor versus prasugrel in a head-to-head comparison in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention.Methods: In this prespecified subgroup analysis, we included 1653 patients with ST-segment-elevation myocardial infarction randomized to receive ticagrelor or prasugrel in the setting of the ISAR REACT-5 trial (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5). The primary end point was the incidence of death, myocardial infarction, or stroke at 1 year after randomization. The secondary end point was the incidence of bleeding defined as BARC (Bleeding Academic Research Consortium) type 3 to 5 bleeding at 1 year after randomization.Results: The primary end point occurred in 83 patients (10.1%) in the ticagrelor group and in 64 patients (7.9%) in the prasugrel group (hazard ratio, 1.31 [95% CI, 0.95-1.82]; P=0.10). One-year incidence of all-cause death (4.9% versus 4.7%; P=0.83), stroke (1.3% versus 1.0%; P=0.46), and definite stent thrombosis (1.8% versus 1.0%; P=0.15) did not differ significantly in patients assigned to ticagrelor or prasugrel. One-year incidence of myocardial infarction (5.3% versus 2.8%; hazard ratio, 1.95 [95% CI, 1.18-3.23]; P=0.010) was higher with ticagrelor than with prasugrel. BARC type 3 to 5 bleeding occurred in 46 patients (6.1%) in the ticagrelor group and in 39 patients (5.1%) in the prasugrel group (hazard ratio, 1.22 [95% CI, 0.80-1.87]; P=0.36).Conclusions: In patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention, there was no significant difference in the primary end point between prasugrel and ticagrelor. Ticagrelor was associated with a significant increase in the risk for recurrent myocardial infarction. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01944800. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
13. Evaluation of Risk-Adjusted Home Time After Acute Myocardial Infarction as a Novel Hospital-Level Performance Metric for Medicare Beneficiaries.
- Author
-
Pandey, Ambarish, Keshvani, Neil, Vaughan-Sarrazin, Mary S., Gao, Yubo, and Girotra, Saket
- Subjects
- *
MYOCARDIAL infarction , *MEDICARE beneficiaries , *NURSING care facilities , *PERCUTANEOUS coronary intervention , *CARDIAC surgery , *RESEARCH , *RESEARCH methodology , *PATIENT readmissions , *HEALTH outcome assessment , *MEDICAL cooperation , *EVALUATION research , *RISK assessment , *COMPARATIVE studies , *RESEARCH funding , *MEDICARE , *DISCHARGE planning , *COMORBIDITY - Abstract
Background: The utility of 30-day risk-standardized readmission rate (RSRR) as a hospital performance metric has been a matter of debate. Home time is a patient-centered outcome measure that accounts for rehospitalization, mortality, and postdischarge care. We aim to characterize risk-adjusted 30-day home time in patients with acute myocardial infarction (AMI) as a hospital-level performance metric and to evaluate associations with 30-day RSRR, 30-day risk-standardized mortality rate (RSMR), and 1-year RSMR.Methods: The study included 984 612 patients with AMI hospitalization across 2379 hospitals between 2009 and 2015 derived from 100% Medicare claims data. Home time was defined as the number of days alive and spent outside of a hospital, skilled nursing facility, or intermediate-/long-term acute care facility 30 days after discharge. Correlations between hospital-level risk-adjusted 30-day home time and 30-day RSRR, 30-day RSMR, and 1-year RSMR were estimated with the Pearson correlation. Reclassification in hospital performance using 30-day home time versus 30-day RSRR and 30-day RSMR was also evaluated.Results: Median hospital-level risk-adjusted 30-day home time was 24.0 days (range, 15.3-29.0 days). Hospitals with higher home time were more commonly academic centers, had available cardiac surgery and rehabilitation services, and had higher AMI volume and percutaneous coronary intervention use during the AMI hospitalization. Of the mean 30-day home time days lost, 58% were to intermediate-/long-term care or skilled nursing facility stays (4.7 days), 30% to death (2.5 days), and 12% to readmission (1.0 days). Hospital-level risk-adjusted 30-day home time was inversely correlated with 30-day RSMR (r=-0.22, P<0.0001) and 30-day RSRR (r=-0.25, P<0.0001). Patients admitted to hospitals with higher risk-adjusted 30-day home time had lower 30-day readmission (quartile 1 versus 4, 21% versus 17%), 30-day mortality rate (5% versus 3%), and 1-year mortality rate (18% versus 12%). Furthermore, 30-day home time reclassified hospital performance status in ≈30% of hospitals versus 30-day RSRR and 30-day RSMR.Conclusions: Thirty-day home time for patients with AMI can be assessed as a hospital-level performance metric with the use of Medicare claims data. It varies across hospitals, is associated with postdischarge readmission and mortality outcomes, and meaningfully reclassifies hospital performance compared with the 30-day RSRR and 30-day RSMR metrics. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
14. Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults.
- Author
-
Lee, Hokyou, Yano, Yuichiro, Cho, So Mi Jemma, Park, Jong Heon, Park, Sungha, Lloyd-Jones, Donald M., and Kim, Hyeon Chang
- Subjects
- *
YOUNG adults , *HYPERTENSION , *BLOOD pressure , *ANTIHYPERTENSIVE agents , *MYOCARDIAL infarction , *HYPERTENSION epidemiology , *RESEARCH , *STROKE , *MORTALITY , *RESEARCH methodology , *CARDIAC contraction , *MEDICAL cooperation , *EVALUATION research , *RISK assessment , *COMPARATIVE studies , *AGE factors in disease , *DIASTOLE (Cardiac cycle) , *HEART failure , *LONGITUDINAL method , *PROPORTIONAL hazards models ,CARDIOVASCULAR disease related mortality - Abstract
Background: Little is known regarding health outcomes associated with isolated systolic hypertension (ISH), isolated diastolic hypertension (IDH), or systolic and diastolic hypertension (SDH) among young adults with stage 1 hypertension, defined using the 2017 American College of Cardiology/American Heart Association blood pressure (BP) guideline.Methods: From a nationwide health screening database, we included 6 424 090 participants, aged 20 to 39 years, who were not taking antihypertensive medication at the baseline examination in 2003 to 2007. Participants were categorized as having normal BP (untreated systolic BP [SBP] <120/diastolic BP [DBP] <80 mm Hg; n=2 665 310); elevated BP (SBP 120-129/DBP <80 mm Hg; n=705 344); stage 1 IDH (SBP <130/DBP 80-89 mm Hg; n=1 271 505); stage 1 ISH (SBP 130-139/DBP <80 mm Hg; n=255 588); stage 1 SDH (SBP 130-139/DBP 80-89 mm Hg; n=711 503); and stage 2 hypertension (SBP ≥140, DBP ≥90 mm Hg; n=814 840). The primary outcome was composite cardiovascular disease (CVD) events, including myocardial infarction, stroke, heart failure, and CVD-related death.Results: The median age of the participants was 30 years and 60.9% were male. Over a median follow-up of 13.2 years, 44 070 new CVD events occurred. With normal BP as the reference, multivariable-adjusted hazard ratios (95% CIs) for CVD events were 1.14 (1.09-1.18) for elevated BP, 1.32 (1.28-1.36) for stage 1 IDH, 1.36 (1.29-1.43) for stage 1 ISH, 1.67 (1.61-1.72) for stage 1 SDH, and 2.40 (2.33-2.47) for stage 2 hypertension.Conclusions: Among young adults, stage 1 ISH, IDH, and SDH were all associated with higher CVD risks than normal BP. The CVD risks of stage 1 ISH and IDH were similar to each other but lower than the risk of stage 1 SDH. Categorizing young adults with stage 1 hypertension further into stage 1 ISH, IDH, and SDH may improve risk stratification for identifying high-risk individuals. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
15. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
- Author
-
Bethel, M. Angelyn, Stevens, Susanna R., Buse, John B., Choi, Jasmine, Gustavson, Stephanie M., Iqbal, Nayyar, Lokhnygina, Yuliya, Mentz, Robert J., Patel, Rishi A., Öhman, Peter, Schernthaner, Guntram, Lecube, Albert, Hernandez, Adrian F., and Holman, Rury R.
- Subjects
- *
GLUCAGON-like peptide-1 receptor , *GLUCAGON-like peptide-1 agonists , *TYPE 2 diabetes , *DRUGS , *PLACEBOS , *DIABETES complications , *STROKE prevention , *STROKE-related mortality , *STROKE , *MYOCARDIAL infarction , *BLOOD sugar , *HYPOGLYCEMIC agents , *RISK assessment , *LONGITUDINAL method ,MYOCARDIAL infarction-related mortality - Abstract
Background: EXSCEL (Exenatide Study of Cardiovascular Event Lowering) assessed the impact of once-weekly exenatide 2 mg versus placebo in patients with type 2 diabetes mellitus, while aiming for glycemic equipoise. Consequently, greater drop-in of open-label glucose-lowering medications occurred in the placebo group. Accordingly, we explored the potential effects of their unbalanced use on major adverse cardiovascular events (MACE), defined as cardiovascular death, nonfatal myocardial infarction or nonfatal stroke, and all-cause mortality (ACM), given that some of these agents are cardioprotective.Methods: Cox hazard models were performed by randomized treatment for drug classes where >5% open-label drop-in glucose-lowering medication occurred, and for glucagon-like peptide-1 receptor agonists (GLP-1 RAs; 3.0%) using three methodologies: drop-in visit right censoring, inverse probability for treatment weighting (IPTW), and applying drug class risk reductions.Results: Baseline glucose-lowering medications for the 14 752 EXSCEL participants (73.1% with previous cardiovascular disease) did not differ between treatment groups. During median 3.2 years follow-up, open-label drop-in occurred in 33.4% of participants, more frequently with placebo than exenatide (38.1% versus 28.8%), with metformin (6.1% versus 4.9%), sulfonylurea (8.7% versus 6.9%), dipeptidyl peptidase-4 inhibitors (10.6% versus 7.5%), SGLT-2i (10.3% versus 8.1%), GLP-1 RA (3.4% versus 2.4%), and insulin (13.8% versus 9.4%). The MACE effect size was not altered meaningfully by right censoring, but the favorable HR for exenatide became nominally significant in the sulfonylurea and any glucose-lowering medication groups, while the ACM HR and p-values were essentially unchanged. IPTW decreased the MACE HR from 0.91 (P=0.061) to 0.85 (P=0.008) and the ACM HR from 0.86 (P=0.016) to 0.81 (P=0.012). Application of literature-derived risk reductions showed no meaningful changes in MACE or ACM HRs or P values, although simulations of substantially greater use of drop-in cardioprotective glucose-lowering agents demonstrated blunting of signal detection.Conclusions: EXSCEL-observed HRs for MACE and ACM remained robust after right censoring or application of literature-derived risk reductions, but the exenatide versus placebo MACE effect size and statistical significance were increased by IPTW. Effects of open-label drop-in cardioprotective medications need to be considered carefully when designing, conducting, and analyzing cardiovascular outcome trials of glucose-lowering agents under the premise of glycemic equipoise. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01144338. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies.
- Author
-
Sorrentino, Sabato, Claessen, Bimmer E., Chandiramani, Rishi, Guedeney, Paul, Vogel, Birgit, Baber, Usman, Rau, Vinuta, Wang, Jin, Krucoff, Mitchell, Kozuma, Ken, Ge, Junbo, Seth, Ashok, Makkar, Raj, Liu, Yuqi, Bangalore, Sripal, Bhatt, Deepak L., Angiolillo, Dominick J., Saito, Shigeru, Neumann, Franz-Josef, and Hermiller, James
- Subjects
- *
PERCUTANEOUS coronary intervention , *CHRONIC kidney failure , *MYOCARDIAL infarction , *CORONARY arteries , *COMORBIDITY , *MEDICAL equipment , *HEMORRHAGIC diseases , *CAUSES of death , *CORONARY artery stenosis , *COMBINATION drug therapy , *DRUG-eluting stents , *MORTALITY , *CHROMIUM , *COBALT , *CORONARY thrombosis , *CARDIOVASCULAR system , *CORONARY restenosis , *TREATMENT effectiveness , *PLATELET aggregation inhibitors , *POLYMERS , *DISEASE prevalence , *KAPLAN-Meier estimator , *SMOKING , *HEMORRHAGE , *LONGITUDINAL method , *PROPORTIONAL hazards models , *DISEASE complications - Abstract
Background: Long-term outcomes in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention with a drug-eluting stent are unclear. Therefore, we aimed to evaluate long-term adverse events in HBR patients undergoing percutaneous coronary intervention with cobalt-chromium everolimus-eluting stent implantation.Methods: We analyzed stratified data from 4 all-comers postapproval registries. Patients with at least 1 of the following criteria were categorized as HBR: age ≥75 years, history of major bleeding (MB), history of stroke, chronic oral anticoagulant use, chronic kidney disease, anemia, or thrombocytopenia. Additionally, in a separate analysis, patients were categorized according to the recently published Academic Research Consortium HBR criteria. The Kaplan-Meier method was used for time-to-event analyses. Coronary thrombotic events (CTE) included myocardial infarction or definite/probable stent thrombosis. MB was defined according to the TIMI (Thrombolysis in Myocardial Infarction) or GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) scales. Impact of CTE and MB on subsequent risk of mortality was assessed using multivariable Cox regression with MB and CTE included as time-updated covariates.Results: Of the total 10 502 patients included, 3507 (33%) were identified as HBR. Compared with non-HBR patients, those at HBR had more comorbidities, higher lesion complexity, and a higher risk of 4-year mortality (Hazard Ratio [HR] 4.38 [95% CI, 3.76-5.11]). Results were qualitatively similar when using Academic Research Consortium criteria to define HBR. Risk of mortality was increased after CTE (HR 5.02 [95% CI, 3.93-6.41]), as well as after MB (HR 4.92 [95% CI, 3.82-6.35]). Of note, this effect was consistent across the spectrum of bleeding risk (P-interaction test 0.97 and 0.06, respectively).Conclusions: Compared with the non-HBR population, HBR patients experienced worse 4-year outcomes after percutaneous coronary intervention with cobalt-chromium everolimus-eluting stent. Both CTE and MB had a significant impact on subsequent risk of mortality irrespective of bleeding risk. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort.
- Author
-
Raphael, Claire E., Roger, Véronique L., Sandoval, Yader, Singh, Mandeep, Bell, Malcolm, Lerman, Amir, Rihal, Charanjit S., Gersh, Bernard J., Lewis, Bradley, Lennon, Ryan J., Jaffe, Allan S., and Gulati, Rajiv
- Subjects
- *
EXPERIMENTAL design , *BIOCHEMICAL oxygen demand , *ARRHYTHMIA , *EARLY death , *MYOCARDIAL infarction , *TROPONIN , *RESEARCH , *CLINICAL trials , *RESEARCH methodology , *DISEASE incidence , *PROGNOSIS , *EVALUATION research , *MEDICAL cooperation , *SEX distribution , *COMPARATIVE studies , *RESEARCH funding , *LONGITUDINAL method ,MYOCARDIAL infarction-related mortality - Abstract
Background: Type 2 myocardial infarction (T2MI) occurs because of an acute imbalance in myocardial oxygen supply and demand in the absence of atherothrombosis. Despite being frequently encountered in clinical practice, the population-based incidence and trends remain unknown, and the long-term outcomes are incompletely characterized.Methods: We prospectively recruited residents of Olmsted County, Minnesota, who experienced an event associated with a cardiac troponin T >99th percentile of a normal reference population (≥0.01 ng/mL) between January 1, 2003, and December 31, 2012. Events were retrospectively classified into type 1 myocardial infarction (T1MI, atherothombotic event), T2MI, or myocardial injury (troponin rise not meeting criteria for myocardial infarction [MI]) using the universal definition. Outcomes were long-term all-cause and cardiovascular mortality and recurrent MI. T2MI was further subclassified by the inciting event for supply/demand mismatch.Results: A total of 5460 patients had at least one cardiac troponin T ≥0.01 ng/mL; 1365 of these patients were classified as index T1MI (age, 68.5±14.8 years; 63% male) and 1054 were classified as T2MI (age, 73.7±15.8 years; 46% male). The annual incidence of T1MI decreased markedly from 202 to 84 per 100 000 persons between 2003 and 2012 (P<0.001), whereas the incidence of T2MI declined from 130 to 78 per 100 000 persons (P=0.02). In comparison with patients with T1MI, patients with T2MI had higher long-term all-cause mortality after adjustment for age and sex, driven by early and noncardiovascular death. Rates of cardiovascular death were similar after either type of MI (hazard ratio, 0.8 [95% CI, 0.7-1.0], P=0.11). Subclassification of T2MI by cause demonstrated a more favorable prognosis when the principal provoking mechanism was arrhythmia, in comparison with postoperative status, hypotension, anemia, and hypoxia. After index T2MI, the most common MI during follow-up was a recurrent T2MI, whereas the occurrence of a new T1MI was relatively rare (estimated rates at 5 years, 9.7% and 1.7%).Conclusions: There has been an evolution in the type of MI occurring in the community over a decade, with the incidence of T2MI now being similar to T1MI. Mortality after T2MI is higher and driven by early and noncardiovascular death. The provoking mechanism of supply/demand mismatch affects long-term survival. These findings underscore the healthcare burden of T2MI and provide benchmarks for clinical trial design. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
18. Letter by Čulić Regarding Article, “Extreme Temperature Events, Fine Particulate Matter, and Myocardial Infarction Mortality”.
- Author
-
Čulić, Viktor
- Subjects
- *
MYOCARDIAL infarction , *PARTICULATE matter , *MORTALITY , *TEMPERATURE - Published
- 2024
- Full Text
- View/download PDF
19. Exercise-Induced Cardiac Troponin I Increase and Incident Mortality and Cardiovascular Events.
- Author
-
Aengevaeren, Vincent L., Hopman, Maria T.E., Thompson, Paul D., Bakker, Esmée A., George, Keith P., Thijssen, Dick H.J., and Eijsvogels, Thijs M.H.
- Subjects
- *
TROPONIN I , *MYOCARDIAL infarction , *HEART failure , *TROPONIN , *HEART beat , *CARDIAC arrest , *MORTALITY - Abstract
Background: Blood concentrations of cardiac troponin above the 99th percentile are a key criterion for the diagnosis of acute myocardial injury and infarction. Troponin concentrations, even below the 99th percentile, predict adverse outcomes in patients and the general population. Elevated troponin concentrations are commonly observed after endurance exercise, but the clinical significance of this increase is unknown. We examined the association between postexercise troponin I concentrations and clinical outcomes in long-distance walkers.Methods: We measured cardiac troponin I concentrations in 725 participants (61 [54-69] yrs) before and immediately after 30 to 55 km of walking. We tested for an association between postexercise troponin I concentrations above the 99th percentile (>0.040 µg/L) and a composite end point of all-cause mortality and major adverse cardiovascular events (myocardial infarction, stroke, heart failure, revascularization, or sudden cardiac arrest). Continuous variables were reported as mean ± standard deviation when normally distributed or median [interquartile range] when not normally distributed.Results: Participants walked 8.3 [7.3-9.3] hours at 68±10% of their maximum heart rate. Baseline troponin I concentrations were >0.040 µg/L in 9 participants (1%). Troponin I concentrations increased after walking (P<.001), with 63 participants (9%) demonstrating a postexercise troponin concentration >0.040 µg/L. During 43 [23-77] months of follow-up, 62 participants (9%) experienced an end point; 29 died and 33 had major adverse cardiovascular events. Compared with 7% with postexercise troponin I ≤0.040 µg/L (log-rank P<.001), 27% of participants with postexercise troponin I concentrations >0.040 µg/L experienced an end point. The hazard ratio was 2.48 (95% CI, 1.29-4.78) after adjusting for age, sex, cardiovascular risk factors (hypertension, hypercholesterolemia or diabetes mellitus), cardiovascular diseases (myocardial infarction, stroke, or heart failure), and baseline troponin I concentrations.Conclusions: Exercise-induced troponin I elevations above the 99th percentile after 30 to 55 km of walking independently predicted higher mortality and cardiovascular events in a cohort of older long-distance walkers. Exercise-induced increases in troponin may not be a benign physiological response to exercise, but an early marker of future mortality and cardiovascular events. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
20. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus.
- Author
-
Rawshani, Aidin, Rawshani, Araz, Sattar, Naveed, Franzén, Stefan, McGuire, Darren K., Eliasson, Björn, Svensson, Ann-Marie, Zethelius, Björn, Miftaraj, Mervete, Rosengren, Annika, and Gudbjörnsdottir, Soffia
- Subjects
- *
TYPE 1 diabetes , *SYSTOLIC blood pressure , *DISEASE risk factors , *DIABETES , *COMPARATIVE studies , *HEART failure , *LONGITUDINAL method , *LOW density lipoproteins , *RESEARCH methodology , *MEDICAL cooperation , *MYOCARDIAL infarction , *HEALTH outcome assessment , *PROGNOSIS , *RESEARCH , *STROKE , *SURVIVAL analysis (Biometry) , *EVALUATION research , *ACQUISITION of data - Abstract
Background: The strength of association and optimal levels for risk factors related to excess risk of death and cardiovascular outcomes in type 1 diabetes mellitus have been sparsely studied.Methods: In a national observational cohort study from the Swedish National Diabetes Register from 1998 to 2014, we assessed relative prognostic importance of 17 risk factors for death and cardiovascular outcomes in individuals with type 1 diabetes mellitus. We used Cox regression and machine learning analyses. In addition, we examined optimal cut point levels for glycohemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol. Patients with type 1 diabetes mellitus were followed up until death or study end on December 31, 2013. The primary outcomes were death resulting from all causes, fatal/nonfatal acute myocardial infarction, fatal/nonfatal stroke, and hospitalization for heart failure.Results: Of 32 611 patients with type 1 diabetes mellitus, 1809 (5.5%) died during follow-up over 10.4 years. The strongest predictors for death and cardiovascular outcomes were glycohemoglobin, albuminuria, duration of diabetes mellitus, systolic blood pressure, and low-density lipoprotein cholesterol. Glycohemoglobin displayed ≈2% higher risk for each 1-mmol/mol increase (equating to ≈22% per 1% glycohemoglobin difference), whereas low-density lipoprotein cholesterol was associated with 35% to 50% greater risk for each 1-mmol/L increase. Microalbuminuria or macroalbuminuria was associated with 2 to 4 times greater risk for cardiovascular complications and death. Glycohemoglobin <53 mmol/mol (7.0%), systolic blood pressure <140 mm Hg, and low-density lipoprotein cholesterol <2.5 mmol/L were associated with significantly lower risk for outcomes observed.Conclusions: Glycohemoglobin, albuminuria, duration of diabetes mellitus, systolic blood pressure, and low-density lipoprotein cholesterol appear to be the most important predictors for mortality and cardiovascular outcomes in patients with type 1 diabetes mellitus. Lower levels for glycohemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol than contemporary guideline target levels appear to be associated with significantly lower risk for outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
21. Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention.
- Author
-
Fanaroff, Alexander C., Roe, Matthew T., Wang, Tracy Y., Peterson, Eric D., Rao, Sunil V., Zakroysky, Pearl, Wojdyla, Daniel, Kaltenbach, Lisa A., Sherwood, Matthew W., Gurm, Hitinder S., Cohen, Mauricio G., and Messenger, John C.
- Subjects
- *
PERCUTANEOUS coronary intervention , *HOSPITAL admission & discharge , *MYOCARDIAL revascularization , *HOSPITAL mortality , *OLDER people , *MYOCARDIAL infarction , *ENDARTERECTOMY , *CARDIOVASCULAR system , *COMPARATIVE studies , *DATABASES , *HOSPITALS , *RESEARCH methodology , *MEDICAL care , *EVALUATION of medical care , *MEDICAL cooperation , *MEDICARE , *REOPERATION , *RESEARCH , *TIME , *EMPLOYEES' workload , *EVALUATION research , *TREATMENT effectiveness , *ACQUISITION of data , *RETROSPECTIVE studies , *PATIENT readmissions - Abstract
Background: Although many studies show an inverse association between operator procedural volume and short-term adverse outcomes after percutaneous coronary intervention (PCI), the association between procedural volume and longer-term outcomes is unknown.Methods: Using the National Cardiovascular Data Registry CathPCI registry data linked with Medicare claims data, we examined the association between operator PCI volume and long-term outcomes among patients ≥65 years of age. Operators were stratified by average annual PCI volume (counting PCIs performed in patients of all ages): low- (<50 PCIs), intermediate- (50-100), and high- (>100) volume operators. One-year unadjusted rates of death and major adverse coronary events (MACEs; defined as death, readmission for myocardial infarction, or unplanned coronary revascularization) were calculated with Kaplan-Meier methods. The proportional hazards assumption was not met, and risk-adjusted associations between operator volume and outcomes were calculated separately from the time of PCI to hospital discharge and from hospital discharge to 1-year follow-up.Results: Between July 1, 2009, and December 31, 2014, 723 644 PCI procedures were performed by 8936 operators: 2553 high-, 2878 intermediate-, and 3505 low-volume operators. Compared with high- and intermediate-volume operators, low-volume operators more often performed emergency PCI, and their patients had fewer cardiovascular comorbidities. Over 1-year follow-up, 15.9% of patients treated by low-volume operators had a MACE compared with 16.9% of patients treated by high-volume operators ( P=0.004). After multivariable adjustment, intermediate- and high-volume operators had a significantly lower rate of in-hospital death than low-volume operators (odds ratio, 0.91; 95% CI, 0.86-0.96 for intermediate versus low; odds ratio, 0.79; 95% CI, 0.75-0.83 for high versus low). There were no significant differences in rates of MACEs, death, myocardial infarction, or unplanned revascularization between operator cohorts from hospital discharge to 1-year follow-up (adjusted hazard ratio for MACEs, 0.99; 95% CI, 0.96-1.01 for intermediate versus low; hazard ratio, 1.01; 95% CI, 0.99-1.04 for high versus low).Conclusions: Unadjusted 1-year outcomes after PCI were worse for older adults treated by operators with higher annual volume; however, patients treated by these operators had more cardiovascular comorbidities. After risk adjustment, higher operator volume was associated with lower in-hospital mortality and no difference in postdischarge MACEs. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
22. Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction.
- Author
-
Jernberg, Tomas, Lindahl, Bertil, Alfredsson, Joakim, Berglund, Ellinor, Bergström, Olle, Engström, Anders, Erlinge, David, Herlitz, Johan, Jumatate, Raluca, Kellerth, Thomas, Lauermann, Jörg, Lindmark, Krister, Lingman, Markus, Ljung, Lina, Nilsson, Carina, Omerovic, Elmir, Pernow, John, Ravn-Fischer, Annica, Sparv, David, and Yndigegn, Troels
- Subjects
- *
MYOCARDIAL infarction , *HEART failure , *OXYGEN therapy , *HOSPITAL care , *CLINICAL trials - Abstract
Background: In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure.Methods: In this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of ≥90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air.Results: A total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84–1.18; P=0.92). During long-term follow-up (median [range], 2.1 [1.0–3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88–1.17; P=0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87–1.33; P=0.52). The results were consistent across all predefined subgroups.Conclusions: Routine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up.Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01787110. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
23. Associations of Variability in Blood Pressure, Glucose and Cholesterol Concentrations, and Body Mass Index With Mortality and Cardiovascular Outcomes in the General Population.
- Author
-
Kim, Mee Kyoung, Han, Kyungdo, Park, Yong-Moon, Kwon, Hyuk-Sang, Kang, Gunseog, Yoon, Kun-Ho, and Lee, Seung-Hwan
- Subjects
- *
BLOOD pressure , *CARDIOVASCULAR agents , *CARDIOVASCULAR diseases , *BODY mass index , *CARDIOVASCULAR diseases risk factors - Abstract
Background: Variability in metabolic parameters, such as fasting blood glucose and cholesterol concentrations, blood pressure, and body weight can affect health outcomes. We investigated whether variability in these metabolic parameters has additive effects on the risk of mortality and cardiovascular outcomes in the general population.Methods: Using nationally representative data from the Korean National Health Insurance System, 6 748 773 people who were free of diabetes mellitus, hypertension, and dyslipidemia and who underwent ≥3 health examinations from 2005 to 2012 were followed to the end of 2015. Variability in fasting blood glucose and total cholesterol concentrations, systolic blood pressure, and body mass index was measured using the coefficient of variation, SD, variability independent of the mean, and average real variability. High variability was defined as the highest quartile of variability. Participants were classified numerically according to the number of high-variability parameters (eg, a score of 4 indicated high variability in all 4 metabolic parameters). Cox proportional hazards models adjusting for age, sex, smoking, alcohol, regular exercise, income, and baseline levels of fasting blood glucose, systolic blood pressure, total cholesterol, and body mass index were used.Results: There were 54 785 deaths (0.8%), 22 498 cases of stroke (0.3%), and 21 452 myocardial infarctions (0.3%) during a median follow-up of 5.5 years. High variability in each metabolic parameter was associated with a higher risk for all-cause mortality, myocardial infarction, and stroke. Furthermore, the risk of outcomes increased significantly with the number of high-variability metabolic parameters. In the multivariable-adjusted model comparing a score of 0 versus 4, the hazard ratios (95% CIs) were 2.27 (2.13-2.42) for all-cause mortality, 1.43 (1.25-1.64) for myocardial infarction, and 1.41 (1.25-1.60) for stroke. Similar results were obtained when modeling the variability using the SD, variability independent of the mean, and average real variability, and in various sensitivity analyses.Conclusions: High variability of fasting blood glucose and total cholesterol levels, systolic blood pressure, and body mass index was an independent predictor of mortality and cardiovascular events. There was a graded association between the number of high-variability parameters and cardiovascular outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
24. Multiple Arterial Grafting Is Associated With Better Outcomes for Coronary Artery Bypass Grafting Patients.
- Author
-
Rocha, Rodolfo V., Tam, Derrick Y., Karkhanis, Reena, Nedadur, Rashmi, Fang, Jiming, Tu, Jack V., Gaudino, Mario, Royse, Alistair, and Fremes, Stephen E.
- Subjects
- *
CORONARY artery bypass , *MYOCARDIAL revascularization , *TRANSPLANTATION of organs, tissues, etc. , *ARTERIAL grafts , *MYOCARDIAL infarction - Abstract
Background: Observational studies have shown better survival in patients undergoing coronary artery bypass grafting (CABG) with 2 arterial grafts compared with 1. However, whether a third arterial graft is associated with incremental benefit remains uncertain. We sought to analyze the outcomes of 3 versus 2 arterial grafts during CABG. As a secondary objective, we compared CABG with 2 or 3 arterial grafts (multiple arterial grafts [MAG]) with CABG using a single arterial graft (SAG).Methods: Retrospective cohort analyses of all patients undergoing primary isolated CABG in Ontario, Canada, from October 2008 to March 2016. Propensity score matching was performed between patients with 3 arterial grafts (3Art group) versus 2 (2Art group). The primary outcome was time to first event of a composite of death, myocardial infarction, stroke, and repeat revascularization (major adverse cardiac and cerebrovascular events). Additional analyses were performed to evaluate the association between MAG versus SAG and long-term outcomes using propensity score matching.Results: Fifty thousand, two hundred thirty patients underwent isolated CABG during our study period; 3044 (6.1%) and 8253 (16.4%) patients had 3 and 2 arterial grafts, respectively, resulting in 2789 propensity score matching pairs for the primary analyses. Mean and maximum follow-up was 4.2 and 8.5 years, respectively. Radial artery grafting was more common in the 3Art versus 2Art group (79.3% versus 65.6%, P<0.01). In-hospital outcomes were not significantly different, including death (3Art 0.8% versus 2Art 0.5%, P=0.26). Up to 8 years, there were no differences in major adverse cardiac and cerebrovascular events (3Art 27%, 95% confidence interval [CI], 24% to 30% versus 2Art 25%, 95% CI, 22% to 28%; hazard ratio [HR], 1.08, 95% CI, 0.94-1.25), death (HR, 1.08; 95% CI, 0.90-1.29), myocardial infarction (HR, 1.15; 95% CI, 0.87-1.51), stroke (HR, 1.39; 95% CI, 0.95-2.06), or repeat revascularization (HR, 1.04; 95% CI, 0.82-1.32). When evaluating MAG versus SAG, 8629 patient pairs were formed using propensity score matching. At 8 years, cumulative incidences of major adverse cardiac and cerebrovascular events (HR, 0.82, 95% CI, 0.77-0.88), survival (HR, 0.80; 95% CI, 0.73-0.88), repeat revascularization (HR, 0.79; 95% CI, 0.69-0.90), and myocardial infarction (HR, 0.83; 95% CI, 0.72-0.97) were superior in the MAG group.Conclusions: CABG with 3 arterial grafts was not associated with increased in-hospital death nor with better clinical outcomes at 8-year follow-up, compared with CABG with 2 arterial grafts. MAG was associated with superior outcomes compared with SAG. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
25. Association of Parkinson Disease With Risk of Cardiovascular Disease and All-Cause Mortality: A Nationwide, Population-Based Cohort Study.
- Author
-
Park, Joo-Hyun, Kim, Do-Hoon, Park, Yong-Gyu, Kwon, Do-Young, Choi, Moonyoung, Jung, Jin-Hyung, and Han, Kyungdo
- Subjects
- *
PARKINSON'S disease , *ORTHOSTATIC hypotension , *COHORT analysis , *NATIONAL health insurance , *CARDIOVASCULAR diseases , *HEART disease related mortality , *RESEARCH , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *LONGITUDINAL method , *DISEASE complications ,CARDIOVASCULAR disease related mortality - Abstract
Keywords: cardiovascular disease; heart failure; mortality; myocardial infarction; neurodegenerative disease; Parkinson disease; stroke EN cardiovascular disease heart failure mortality myocardial infarction neurodegenerative disease Parkinson disease stroke 1205 1207 3 04/20/20 20200407 NES 200407 Parkinson disease (PD) is the second most common neurodegenerative disorder and affects 1% to 3% of people aged >65 years. CVDs, such as myocardial infarction (MI), ischemic stroke, and congestive heart failure (CHF), are the most common medical conditions in older people. Hazard ratios of acute myocardial infarction, ischemic stroke, congestive heart failure, and all-cause mortality in the Parkinson disease (PD) group compared with those in the non-PD group. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
26. Is Cardioprotection Salvageable?
- Author
-
Heusch, Gerd and Gersh, Bernard J.
- Subjects
- *
METOPROLOL , *ALDOSTERONE antagonists , *MYOCARDIAL infarction , *ACE inhibitors , *THERAPEUTICS , *RESEARCH , *CLINICAL trials , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *COMPARATIVE studies , *IMPACT of Event Scale ,DEVELOPING countries - Abstract
Keywords: heart failure; mortality; myocardial infarction EN heart failure mortality myocardial infarction 415 417 3 04/20/20 20200211 NES 200211 Despite decades of preclinical and clinical proof-of-concept studies that have demonstrated that cardioprotection results in unequivocal infarct size reduction, translation into a benefit in clinical outcomes has been very disappointing. Perhaps the answer lies in the dramatic changes in the natural history of myocardial infarction and the revolutionary impact of reperfusion therapy. Mortality has declined steadily and substantially, with faster and better reperfusion therapies and the use of potent platelet inhibition and drugs that attenuate postinfarct remodeling, namely angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
27. Myocardial Scar and Mortality in Severe Aortic Stenosis.
- Author
-
Musa, Tarique A., Treibel, Thomas A., Vassiliou, Vassiliou S., Captur, Gabriella, Singh, Anvesha, Chin, Calvin, Dobson, Laura E., Pica, Silvia, Loudon, Margaret, Malley, Tamir, Rigolli, Marzia, Foley, James R.J., Bijsterveld, Petra, Law, Graham R., Dweck, Marc R., Myerson, Saul G., McCann, Gerry P., Prasad, Sanjay K., Moon, James C., and Greenwood, John P.
- Subjects
- *
AORTIC stenosis , *MORTALITY , *MYOCARDIAL infarction , *HEART failure , *CHEMICAL elements , *COMPARATIVE studies , *ECHOCARDIOGRAPHY , *PROSTHETIC heart valves , *LONGITUDINAL method , *MAGNETIC resonance imaging , *RESEARCH methodology , *MEDICAL cooperation , *MYOCARDIUM , *RESEARCH , *SCARS , *EVALUATION research , *TREATMENT effectiveness , *CONTRAST media , *PROPORTIONAL hazards models , *SEVERITY of illness index , *KAPLAN-Meier estimator ,AORTIC valve surgery - Abstract
Background: Aortic valve replacement (AVR) for aortic stenosis is timed primarily on the development of symptoms, but late surgery can result in irreversible myocardial dysfunction and additional risk. The aim of this study was to determine whether the presence of focal myocardial scar preoperatively was associated with long-term mortality.Methods: In a longitudinal observational outcome study, survival analysis was performed in patients with severe aortic stenosis listed for valve intervention at 6 UK cardiothoracic centers. Patients underwent preprocedural echocardiography (for valve severity assessment) and cardiovascular magnetic resonance for ventricular volumes, function and scar quantification between January 2003 and May 2015. Myocardial scar was categorized into 3 patterns (none, infarct, or noninfarct patterns) and quantified with the full width at half-maximum method as percentage of the left ventricle. All-cause mortality and cardiovascular mortality were tracked for a minimum of 2 years.Results: Six hundred seventy-four patients with severe aortic stenosis (age, 75±14 years; 63% male; aortic valve area, 0.38±0.14 cm2/m2; mean gradient, 46±18 mm Hg; left ventricular ejection fraction, 61.0±16.7%) were included. Scar was present in 51% (18% infarct pattern, 33% noninfarct). Management was surgical AVR (n=399) or transcatheter AVR (n=275). During follow-up (median, 3.6 years), 145 patients (21.5%) died (52 after surgical AVR, 93 after transcatheter AVR). In multivariable analysis, the factors independently associated with all-cause mortality were age (hazard ratio [HR], 1.50; 95% CI, 1.11-2.04; P=0.009, scaled by epochs of 10 years), Society of Thoracic Surgeons score (HR, 1.12; 95% CI, 1.03-1.22; P=0.007), and scar presence (HR, 2.39; 95% CI, 1.40-4.05; P=0.001). Scar independently predicted all-cause (26.4% versus 12.9%; P<0.001) and cardiovascular (15.0% versus 4.8%; P<0.001) mortality, regardless of intervention (transcatheter AVR, P=0.002; surgical AVR, P=0.026 [all-cause mortality]). Every 1% increase in left ventricular myocardial scar burden was associated with 11% higher all-cause mortality hazard (HR, 1.11; 95% CI, 1.05-1.17; P<0.001) and 8% higher cardiovascular mortality hazard (HR, 1.08; 95% CI, 1.01-1.17; P<0.001).Conclusions: In patients with severe aortic stenosis, late gadolinium enhancement on cardiovascular magnetic resonance was independently associated with mortality; its presence was associated with a 2-fold higher late mortality. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
28. Hospital Readmission After Perioperative Acute Myocardial Infarction Associated With Noncardiac Surgery.
- Author
-
Smilowitz, Nathaniel R., Beckman, Joshua A., Sherman, Scott E., and Berger, Jeffrey S.
- Subjects
- *
MYOCARDIAL infarction , *PATIENT readmissions , *HOSPITAL care , *SURGERY , *MORTALITY , *CARDIOVASCULAR disease diagnosis , *COMMUNICABLE disease diagnosis , *HEMORRHAGE complications , *HEMORRHAGE diagnosis , *CARDIOVASCULAR diseases , *COMMUNICABLE diseases , *RESEARCH funding , *ACUTE diseases , *HOSPITAL mortality , *PERIOPERATIVE care , *DISEASE complications ,MYOCARDIAL infarction diagnosis ,MYOCARDIAL infarction-related mortality - Abstract
Background: Acute myocardial infarction (AMI) is a major cardiovascular complication of noncardiac surgery. We aimed to evaluate the frequency, causes, and outcomes of 30-day hospital readmission after perioperative AMI.Methods: Patients who were diagnosed with AMI during hospitalization for major noncardiac surgery were identified using the 2014 US Nationwide Readmission Database. Rates, causes, and costs of 30-day readmissions after noncardiac surgery with and without perioperative AMI were identified.Results: Among 3 807 357 hospitalizations for major noncardiac surgery, 8085 patients with perioperative AMI were identified. A total of 1135 patients (14.0%) with perioperative AMI died in-hospital during the index admission. Survivors of perioperative AMI were more likely to be readmitted within 30 days than surgical patients without perioperative AMI (19.1% versus 6.5%, P<0.001). The most common indications for 30-day rehospitalization were management of infectious complications (30.0%), cardiovascular complications (25.3%), and bleeding (10.4%). In-hospital mortality during hospital readmission in the first 30 days after perioperative AMI was 11.3%. At 6 months, the risk of death was 17.6% and ≥1 hospital readmission was 36.2%.Conclusions: Among patients undergoing noncardiac surgery who develop a perioperative MI, ≈1 in 3 suffer from in-hospital death or hospital readmission in the first 30 days after discharge. Strategies to improve outcomes of surgical patients early after perioperative AMI are warranted. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
29. Mortality and Cerebrovascular Events After Heart Rhythm Disorder Management Procedures.
- Author
-
Lee, Justin Z., Ling, Jayna, Diehl, Nancy N., Hodge, David O., Padmanabhan, Deepak, Killu, Ammar M., Madhavan, Malini, Noseworthy, Peter A., Kapa, Suraj, McLeod, Christopher J., Yong-Mei Cha, Deshmukh, Abhishek J., Srivathsan, Komandoor, Kusumoto, Fred M., Win-Kuang Shen, Friedman, Paul A., Munger, Thomas M., Asirvatham, Samuel J., Packer, Douglas L., and Mulpuru, Siva K.
- Subjects
- *
CARDIAC surgery , *CORONARY artery bypass , *MYOCARDIAL infarction , *ATRIAL fibrillation , *PERCUTANEOUS coronary intervention , *ARRHYTHMIA diagnosis , *ARRHYTHMIA treatment , *TRANSIENT ischemic attack diagnosis , *STROKE diagnosis , *STROKE-related mortality , *ARRHYTHMIA , *CARDIAC pacemakers , *CARDIAC tamponade , *COMPARATIVE studies , *CAUSES of death , *HEART function tests , *IMPLANTABLE cardioverter-defibrillators , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RISK assessment , *STROKE , *TIME , *TRANSIENT ischemic attack , *EVALUATION research , *TREATMENT effectiveness , *RETROSPECTIVE studies , *MEDICAL device removal , *ABLATION techniques , *HOSPITAL mortality - Abstract
Background: Recognition of rates and causes of hard, patient-centered outcomes of death and cerebrovascular events (CVEs) after heart rhythm disorder management (HRDM) procedures is an essential step for the development of quality improvement programs in electrophysiology laboratories. Our primary aim was to assess and characterize death and CVEs (stroke or transient ischemic attack) after HRDM procedures over a 17-year period.Methods: We performed a retrospective cohort study of all patients undergoing HRDM procedures between January 2000 and November 2016 at the Mayo Clinic. Patients from all 3 tertiary academic centers (Rochester, Phoenix, and Jacksonville) were included in the study. All in-hospital deaths and CVEs after HRDM procedures were identified and were further characterized as directly or indirectly related to the HRDM procedure. Subgroup analysis of death and CVE rates was performed for ablation, device implantation, electrophysiology study, lead extraction, and defibrillation threshold testing procedures.Results: A total of 48 913 patients (age, 65.7±6.6 years; 64% male) who underwent a total of 62 065 HRDM procedures were included in the study. The overall mortality and CVE rates in the cohort were 0.36% (95% confidence interval [CI], 0.31-0.42) and 0.12% (95% CI, 0.09-0.16), respectively. Patients undergoing lead extraction had the highest overall mortality rate at 1.9% (95% CI, 1.34-2.61) and CVE rate at 0.62% (95% CI, 0.32-1.07). Among patients undergoing HRDM procedures, 48% of deaths directly related to the HDRM procedure were among patients undergoing device implantation procedures. Overall, cardiac tamponade was the most frequent direct cause of death (40%), and infection was the most common indirect cause of death (29%). The overall 30-day mortality rate was 0.76%, with the highest being in lead extraction procedures (3.08%), followed by device implantation procedures (0.94%).Conclusions: Half of the deaths directly related to an HRDM procedure were among the patients undergoing device implantation procedures, with cardiac tamponade being the most common cause of death. This highlights the importance of the development of protocols for the quick identification and management of cardiac tamponade even in procedures typically believed to be lower risk such as device implantation. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
30. Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015.
- Author
-
Puymirat, Etienne, Simon, Tabassome, Cayla, Guillaume, Cottin, Yves, Elbaz, Meyer, Coste, Pierre, Lemesle, Gilles, Motreff, Pascal, Popovic, Batric, Khalife, Khalife, Labèque, Jean-Noel, Perret, Thibaut, Le Ray, Christophe, Orion, Laurent, Jouve, Bernard, Blanchard, Didier, Peycher, Patrick, Silvain, Johanne, Steg, Philippe Gabriel, and Goldstein, Patrick
- Subjects
- *
MYOCARDIAL infarction , *PATIENT management , *HEALTH outcome assessment , *MEDICAL registries , *MEDICAL care , *MANAGEMENT - Abstract
Background: ST-segment-elevation myocardial infarction (STEMI) and non-ST-segment-elevation myocardial infarction (NSTEMI) management has evolved considerably over the past 2 decades. Little information on mortality trends in the most recent years is available. We assessed trends in characteristics, treatments, and outcomes for acute myocardial infarction in France between 1995 and 2015.Methods: We used data from 5 one-month registries, conducted 5 years apart, from 1995 to 2015, including 14 423 patients with acute myocardial infarction (59% STEMI) admitted to cardiac intensive care units in metropolitan France.Results: From 1995 to 2015, mean age decreased from 66±14 to 63±14 years in patients with STEMI; it remained stable (68±14 years) in patients with NSTEMI, whereas diabetes mellitus, obesity, and hypertension increased. At the acute stage, intended primary percutaneous coronary intervention increased from 12% (1995) to 76% (2015) in patients with STEMI. In patients with NSTEMI, percutaneous coronary intervention ≤72 hours from admission increased from 9% (1995) to 60% (2015). Six-month mortality consistently decreased in patients with STEMI from 17.2% in 1995 to 6.9% in 2010 and 5.3% in 2015; it decreased from 17.2% to 6.9% in 2010 and 6.3% in 2015 in patients with NSTEMI. Mortality still decreased after 2010 in patients with STEMI without reperfusion therapy, whereas no further mortality gain was found in patients with STEMI with reperfusion therapy or in patients with NSTEMI, whether or not they were treated with percutaneous coronary intervention.Conclusions: Over the past 20 years, 6-month mortality after acute myocardial infarction has decreased considerably for patients with STEMI and NSTEMI. Mortality figures continued to decline in patients with STEMI until 2015, whereas mortality in patients with NSTEMI appears stable since 2010. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
31. Pathophysiology of Takotsubo Syndrome.
- Author
-
Pelliccia, Francesco, Kaski, Juan Carlos, Crea, Filippo, and Camici, Paolo G.
- Subjects
- *
TAKOTSUBO cardiomyopathy , *HEART ventricle diseases , *MYOCARDIAL infarction , *ACUTE coronary syndrome , *MORTALITY , *NERVE endings , *CATECHOLAMINES , *ELECTROCARDIOGRAPHY , *ESTROGEN , *SEX distribution , *PSYCHOLOGICAL stress , *PSYCHOLOGICAL factors , *PSYCHOLOGY - Abstract
Originally described by Japanese authors in the 1990s, Takotsubo syndrome (TTS) generally presents as an acute myocardial infarction characterized by severe left ventricular dysfunction. TTS, however, differs from an acute coronary syndrome because patients have generally a normal coronary angiogram and left ventricular dysfunction, which extends beyond the territory subtended by a single coronary artery and recovers within days or weeks. The prognosis was initially thought to be benign, but subsequent studies have demonstrated that both short-term mortality and long-term mortality are higher than previously recognized. Indeed, mortality reported during the acute phase in hospitalized patients is ≈4% to 5%, a figure comparable to that of ST-segment-elevation myocardial infarction in the era of primary percutaneous coronary interventions. Despite extensive research, the cause and pathogenesis of TTS remain incompletely understood. The aim of the present review is to discuss the pathophysiology of TTS with particular emphasis on the role of the central and autonomic nervous systems. Different emotional or psychological stressors have been identified to precede the onset of TTS. The anatomic structures that mediate the stress response are found in both the central and autonomic nervous systems. Acute stressors induce brain activation, increasing bioavailability of cortisol and catecholamine. Both circulating epinephrine and norepinephrine released from adrenal medullary chromaffin cells and norepinephrine released locally from sympathetic nerve terminals are significantly increased in the acute phase of TTS. This catecholamine surge leads, through multiple mechanisms, that is, direct catecholamine toxicity, adrenoceptor-mediated damage, epicardial and microvascular coronary vasoconstriction and/or spasm, and increased cardiac workload, to myocardial damage, which has a functional counterpart of transient apical left ventricular ballooning. The relative preponderance among postmenopausal women suggests that estrogen deprivation may play a facilitating role, probably mediated by endothelial dysfunction. Despite the substantial improvement in our understanding of the pathophysiology of TTS, a number of knowledge gaps remain. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. Depression Treatment and 1-Year Mortality After Acute Myocardial Infarction: Insights From the TRIUMPH Registry (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status).
- Author
-
Smolderen, Kim G., Buchanan, Donna M., Gosch, Kensey, Whooley, Mary, Chan, Paul S., Vaccarino, Viola, Parashar, Susmita, Shah, Amit J., Ho, P. Michael, and Spertus, John A.
- Subjects
- *
MENTAL depression , *THERAPEUTICS , *DISEASE prevalence , *QUALITY of life , *MEDICAL records , *ANTIDEPRESSANTS , *DIAGNOSIS of mental depression , *MYOCARDIAL infarction , *MYOCARDIAL infarction treatment , *COMPARATIVE studies , *CAUSES of death , *HEALTH status indicators , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *MENTAL health , *PSYCHOLOGICAL tests , *QUESTIONNAIRES , *RESEARCH , *RESEARCH funding , *RISK assessment , *TIME , *EVALUATION research , *TREATMENT effectiveness , *ACQUISITION of data , *PROPORTIONAL hazards models , *KAPLAN-Meier estimator , *PSYCHOLOGY ,MYOCARDIAL infarction-related mortality ,MYOCARDIAL infarction diagnosis - Abstract
Background: Depression among patients with acute myocardial infarction (AMI) is prevalent and associated with an adverse quality of life and prognosis. Despite recommendations from some national organizations to screen for depression, it is unclear whether treatment of depression in patients with AMI is associated with better outcomes. We aimed to determine whether the prognosis of patients with treated versus untreated depression differs.Methods: The TRIUMPH study (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status) is an observational multicenter cohort study that enrolled 4062 patients aged ≥18 years with AMI between April 11, 2005, and December 31, 2008, from 24 US hospitals. Research coordinators administered the Patient Health Questionnaire-9 (PHQ-9) during the index AMI admission. Depression was defined by a PHQ-9 score of ≥10. Depression was categorized as treated if there was documentation of a discharge diagnosis, medication prescribed for depression, or referral for counseling, and as untreated if none of these 3 criteria was documented in the medical records despite a PHQ score ≥10. One-year mortality was compared between patients with AMI having: (1) no depression (PHQ-9<10; reference); (2) treated depression; and (3) untreated depression adjusting for demographics, AMI severity, and clinical factors.Results: Overall, 759 (18.7%) patients met PHQ-9 criteria for depression and 231 (30.4%) were treated. In comparison with 3303 patients without depression, the 231 patients with treated depression had 1-year mortality rates that were not different (6.1% versus 6.7%; adjusted hazard ratio, 1.12; 95% confidence interval, 0.63-1.99). In contrast, the 528 patients with untreated depression had higher 1-year mortality in comparison with patients without depression (10.8% versus 6.1%; adjusted hazard ratio, 1.91; 95% confidence interval, 1.39-2.62).Conclusions: Although depression in patients with AMI is associated with increased long-term mortality, this association may be confined to patients with untreated depression. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
33. Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology.
- Author
-
Lloyd-Jones, Donald M., Huffman, Mark D., Karmali, Kunal N., Sanghavi, Darshak M., Wright, Janet S., Pelser, Colleen, Gulati, Martha, Masoudi, Frederick A., Goff Jr., David C., and Goff, David C Jr
- Subjects
- *
CARDIOVASCULAR diseases , *MEDICARE , *ASPIRIN , *SMOKING , *CHOLESTEROL - Abstract
The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes-the leading causes of mortality-through several public health and healthcare strategies by 2017. The American Heart Association and American College of Cardiology support the program. The Cardiovascular Risk Reduction Model was developed by Million Hearts and the Center for Medicare & Medicaid Services as a strategy to assess a value-based payment approach toward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implementing cardiovascular preventive strategies to manage the "ABCS" (aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smoking cessation). The purpose of this special report is to describe the development and intended use of the Million Hearts Longitudinal ASCVD Risk Assessment Tool. The Million Hearts Tool reinforces and builds on the "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk" by allowing clinicians to estimate baseline and updated 10-year ASCVD risk estimates for primary prevention patients adhering to the appropriate ABCS over time, alone or in combination. The tool provides updated risk estimates based on evidence from high-quality systematic reviews and meta-analyses of the ABCS therapies. This novel approach to personalized estimation of benefits from risk-reducing therapies in primary prevention may help target therapies to those in whom they will provide the greatest benefit, and serves as the basis for a Center for Medicare & Medicaid Services program designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
34. Glycated Hemoglobin A1c Levels in Type 1 Diabetes Mellitus and Outcomes After Myocardial Infarction.
- Author
-
Nyström, Thomas, Sartipy, Ulrik, Contardi, Andrea, Lind, Marcus, Bellocco, Rino, Eliasson, Björn, Svensson, Ann-Marie, and Holzmann, Martin J.
- Subjects
- *
TYPE 1 diabetes , *MYOCARDIAL infarction , *GLYCOSYLATED hemoglobin - Abstract
The article presents a research study on glycated hemoglobin A1c levels in type 1 diabetes mellitus (T1DM) and outcomes after myocardial infarction (MI). The study comprised all T1DM patients who had an MI between 1995 to 2013 in Sweden, identified using the National Patient Register. It is concluded that higher HbA1c levels were associated with a greater risk of recurrent MI, death, and heart failure.
- Published
- 2019
- Full Text
- View/download PDF
35. Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study.
- Author
-
Zhu-Ming Zhang, Rautaharju, Pentti M., Prineas, Ronald J., Rodriguez, Carlos J., Loehr, Laura, Rosamond, Wayne D., Kitzman, Dalane, Couper, David, Soliman, Elsayed Z., and Zhang, Zhu-Ming
- Subjects
- *
RACIAL differences , *MYOCARDIAL infarction , *DISEASE incidence , *ATHEROSCLEROSIS , *BLACK people , *HUMAN reproduction , *LONGITUDINAL method , *MORTALITY , *POPULATION , *PROGNOSIS , *RESEARCH funding , *WHITE people , *RESIDENTIAL patterns , *DIAGNOSIS ,SEX differences (Biology) ,MYOCARDIAL infarction diagnosis ,MYOCARDIAL infarction-related mortality - Abstract
Background: Race and sex differences in silent myocardial infarction (SMI) are not well established.Methods and Results: The analysis included 9498 participants from the Atherosclerosis Risk in Communities (ARIC) study who were free of cardiovascular disease at baseline (visit 1, 1987-1989). Incident SMI was defined as ECG evidence of MI without clinically documented MI (CMI) after the baseline until ARIC visit 4 (1996-1998). Coronary heart disease and all-cause deaths were ascertained starting from ARIC visit 4 until 2010. During a median follow-up of 8.9 years, 317 participants (3.3%) developed SMI and 386 (4.1%) developed CMI. The incidence rates of both SMI and CMI were higher in men (5.08 and 7.96 per 1000-person years, respectively) than in women (2.93 and 2.25 per 1000-person years, respectively; P<0.0001 for both). Blacks had a nonsignificantly higher rate of SMI than whites (4.45 versus 3.69 per 1000-person years; P=0.217), but whites had higher rate of CMI than blacks (5.04 versus 3.24 per 1000-person years; P=0.002). SMI and CMI (compared with no MI) were associated with increased risk of coronary heart disease death (hazard ratio, 3.06 [95% confidence interval, 1.88-4.99] and 4.74 [95% confidence interval, 3.26-6.90], respectively) and all-cause mortality (hazard ratio, 1.34 [95% confidence interval, 1.09-1.65] and 1.55 [95% confidence interval, 1.30-1.85], respectively). However, SMI and CMI were associated with increased mortality among both men and women, with potentially greater increased risk among women (interaction P=0.089 and 0.051, respectively). No significant interactions by race were detected.Conclusions: SMI represents >45% of incident MIs and is associated with poor prognosis. Race and sex differences in the incidence and prognostic significance of SMI exist that may warrant considering SMI in personalized assessments of coronary heart disease risk. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
36. Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials.
- Author
-
Kragholm, Kristian, Goldstein, Sarah A., Qinghong Yang, Lopes, Renato D., Schulte, Phillip J., Bernacki, Gwen M., White, Harvey D., Mahaffey, Kenneth W., Giugliano, Robert P., Armstrong, Paul W., Harrington, Robert A., Tricoci, Pierluigi, Van de Werf, Frans, Alexander, John H., Alexander, Karen P., Newby, L. Kristin, and Yang, Qinghong
- Subjects
- *
TREATMENT of acute coronary syndrome , *CLINICAL trials , *EVIDENCE-based medicine , *MORTALITY , *MYOCARDIAL infarction , *AGE distribution , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RESEARCH funding , *EVALUATION research , *TREATMENT effectiveness , *PATIENT selection , *ACUTE coronary syndrome , *DIAGNOSIS - Abstract
Background: Representation by age ensures appropriate translation of clinical trial results to practice, but, historically, older patients have been underrepresented in clinical trial populations. As the general population has aged, it is unknown whether clinical trial enrollment has changed in parallel.Methods and Results: We studied time trends in enrollment, clinical characteristics, treatment, and outcomes by age among 76 141 patients with non-ST-segment-elevation acute coronary syndrome enrolled in 11 phase III clinical trials over 17 years (1994-2010). Overall, 19.7% of patients were ≥75 years; this proportion increased from 16% during 1994 to 1997 to 21% during 1998 to 2001 and 23.2% during 2002 to 2005, but declined to 20.2% in 2006 to 2010. The number of comorbidities increased with successive time periods irrespective of age. There were substantial increases in the use of evidence-based medication in-hospital and at discharge regardless of age. Although predicted 6-month mortality increased slightly over time, observed 6-month mortality declined significantly in all age strata (1994-1997 versus 2006-2010: <65 years: 3.0% versus 1.9%; 65-74 years: 7.5% versus 3.4%; 75-79 years: 13.0% versus 6.5%; 80-84 years: 17.6% versus 8.2%; and ≥85 years: 24.8% versus 12.6%).Conclusions: The distribution of enrollment by age in phase III non-ST-segment-elevation acute coronary syndrome trials was unchanged over time. Irrespective of age, post-myocardial infarction mortality decreased significantly over time, concurrent with increased evidence-based care and despite increasing comorbidities.Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00089895. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
37. Trends in Modifiable Risk Factors Are Associated With Declining Incidence of Hospitalized and Nonhospitalized Acute Coronary Heart Disease in a Population.
- Author
-
Mannsverk, Jan, Wilsgaard, Tom, Mathiesen, Ellisiv B., Løchen, Maja-Lisa, Rasmussen, Knut, Thelle, Dag S., Njølstad, Inger, Arnesdatter Hopstock, Laila, Harald Bønaa, Kaare, Hopstock, Laila Arnesdatter, and Bønaa, Kaare Harald
- Subjects
- *
CORONARY disease , *MYOCARDIAL infarction risk factors , *MEDICAL care of cardiac patients , *MOLECULAR epidemiology , *SUDDEN death , *DIAGNOSIS , *TREATMENT of acute coronary syndrome , *HOSPITAL care , *LONGITUDINAL method , *MORTALITY , *PUBLIC health surveillance , *DISEASE incidence , *ACUTE coronary syndrome - Abstract
Background: Few studies have used individual person data to study whether contemporary trends in the incidence of coronary heart disease are associated with changes in modifiable coronary risk factors.Methods and Results: We identified 29 582 healthy men and women ≥25 years of age who participated in 3 population surveys conducted between 1994 and 2008 in Tromsø, Norway. Age- and sex-adjusted incidence rates were calculated for coronary heart disease overall, out-of-hospital sudden death, and hospitalized ST-segment-elevation and non-ST-segment-elevation myocardial infarction. We measured coronary risk factors at each survey and estimated the relationship between changes in risk factors and changes in incidence trends. A total of 1845 participants had an incident acute coronary heart disease event during 375 064 person-years of follow-up from 1994 to 2010. The age- and sex-adjusted incidence of total coronary heart disease decreased by 3% (95% confidence interval, 2.0-4.0; P<0.001) each year. This decline was driven by decreases in out-of-hospital sudden death and hospitalized ST-segment-elevation myocardial infarction. Changes in coronary risk factors accounted for 66% (95% confidence interval, 48-97; P<0.001) of the decline in total coronary heart disease. Favorable changes in cholesterol contributed 32% to the decline, whereas blood pressure, smoking, and physical activity each contributed 14%, 13%, and 9%, respectively.Conclusions: We observed a substantial decline in the incidence of coronary heart disease that was driven by reductions in out-of-hospital sudden death and hospitalized ST-segment-elevation myocardial infarction. Changes in modifiable coronary risk factors accounted for 66% of the decline in coronary heart disease events. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
38. Association of Urinary Nitrate With Lower Prevalence of Hypertension and Stroke and With Reduced Risk of Cardiovascular Mortality.
- Author
-
Mendy, Angelico
- Subjects
- *
PHYSIOLOGICAL effects of nitrates , *CARDIOVASCULAR diseases risk factors , *CANCER risk factors , *HEALTH & Nutrition Examination Survey , *HYPERTENSION , *STROKE , *MYOCARDIAL infarction , *HYPERTENSION epidemiology , *STROKE diagnosis , *CARDIOVASCULAR diseases , *NITRATES , *SURVEYS , *LOGISTIC regression analysis , *DISEASE prevalence , *PROPORTIONAL hazards models ,CARDIOVASCULAR disease related mortality - Abstract
The article discusses a study on the link of urinary nitrate with cardiovascular disease (CVD) prevalence and mortality as primary outcomes and with cancer and all-cause mortality as secondary outcomes. Data from the National Health and Nutrition Examination Survey (NHANES) conducted from 2005 to 2014 in the U.S. were analyzed. The prevalence of hypertension, stroke, and myocardial infarction is noted. Urinary nitrate is found to be associated with a lower prevalence of hypertension and stroke.
- Published
- 2018
- Full Text
- View/download PDF
39. Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
- Author
-
Angelyn Bethel, M., McMurray, John J. V., and Bethel, M Angelyn
- Subjects
- *
CARDIOVASCULAR agents , *CARDIOVASCULAR diseases risk factors , *GLYCOSURIA , *BLOOD sugar , *HEART failure - Abstract
The article discusses the cardiovascular outcomes of sodium glucose-cotransporter-2 inhibitors (SGLT-2i). SGLT-2i inhibit glucose uptake in the proximal renal tubule which lead to increased glycosuria and in turn a decrease in blood glucose. It was noted that in both EMPA-REG OUTCOME and the CANVAS Program, SGLT-2i resulted in reduction in the 3-component major adverse cardiovascular event outcome.
- Published
- 2018
- Full Text
- View/download PDF
40. Race, Socioeconomic Status, and Life Expectancy After Acute Myocardial Infarction.
- Author
-
Bucholz, Emily M., Shuangge Ma, Normand, Sharon-Lise T., Krumholz, Harlan M., and Ma, Shuangge
- Abstract
Background: Previous studies have been unable to disentangle the negative associations of black race and low socioeconomic status (SES) with long-term outcomes of patients after acute myocardial infarction (AMI). Such information could assist in efforts to address both racial and socioeconomic disparities.Methods and Results: We used data from the Cooperative Cardiovascular Project, a prospective cohort study of Medicare beneficiaries hospitalized with AMI with 17 years of follow-up, to evaluate the relationship between race, area-level SES (measured by zip code-level median household income), and life expectancy after AMI. Life expectancy was estimated by using Cox proportional hazards regression with extrapolation using exponential models. Of the 141 095 patients with AMI, 6.3% were black and 6.8% resided in low-SES areas; 26% of black patients lived in low-SES areas in comparison with 5.7% of white patients. Post-myocardial infarction life expectancy estimates were shorter for black patients than for white patients across all socioeconomic levels in patients ≤ 75 years of age. After adjustment for patient and treatment characteristics, the association between race and life expectancy persisted but was attenuated. Younger black patients (<68 years) had shorter life expectancies than white patients, whereas older black patients had longer life expectancies. The largest white-black gap in life expectancy occurred in patients residing in high- and medium-SES areas (P=0.02 interaction).Conclusions: Black and white patients residing in low-SES areas have similar life expectancies after AMI, which are lower than those living in higher-SES areas. Racial disparities were most prominent among patients living in high-SES areas. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
41. Does Timing of Coronary Artery Bypass Surgery Affect Early and Long-Term Outcomes in Patients With Non–ST-Segment–Elevation Myocardial Infarction?
- Author
-
Davierwala, Piroze M., Verevkin, Alexander, Leontyev, Sergey, Misfeld, Martin, Borger, Michael A., and Mohr, Friedrich W.
- Subjects
- *
CORONARY artery bypass , *CARDIAC surgery , *MYOCARDIAL infarction treatment , *CORONARY heart disease treatment , *HEART disease related mortality - Abstract
Background—Current guidelines do not provide recommendations for optimal timing of coronary artery bypass surgery (CABG) in patients with non-ST-segment-elevation myocardial infarction. Our study aimed to determine the impact of CABG timing on early and late outcomes in patients with non-ST-segment-elevation myocardial infarction. Methods and Results—A total of 758 patients underwent CABG within 21 days after non-ST-segment-elevation myocardial infarction between January 2008 and December 2012 at our institution. The patients were divided into 3 groups according to the time interval between symptom onset and CABG: group A, <24 hours (133 patients); group B, 24 to 72 hours (192 patients); and group C, >72 hours to 21 days (433 patients). Predictors of in-hospital and long-term mortality were identified by logistic and Cox regression analyses, respectively. Overall in-hospital mortality was 5.1% (39 patients): 6.0%, 4.7%, and 5.1% in groups A, B, and C (P=0.9), respectively. A total of 118 patients died during follow-up. The 5-year survival was 73.1±2%, with a nonsignificant trend toward better survival in groups A (78.2±4%) and C (75.4±3%) compared with group B (63.6±5%; log-rank P=0.06). Renal insufficiency and LMD were independent predictors of in-hospital (odds ratio, 3.1; P=0.001; and odds ratio, 3.1; P=0.002) and long-term mortality (hazard ratio, 1.7; P=0.004; and hazard ratio, 1.5; P=0.02), whereas administration of P2Y12 inhibitors was protective (odds ratio, 0.3; P=0.01). Conclusions—Emergent CABG within 24 hours of non-ST-segment-elevation myocardial infarction is associated with in-hospital mortality and long-term outcomes similar to those of CABG performed after 3 days, despite a higher risk profile. CABG performed between 24 to 72 hours showed a nonsignificant trend toward poorer long-term outcomes. Dual antiplatelet therapy until surgery is beneficial, whereas renal insufficiency and left main disease increase the risk of early and late death. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
42. Percutaneous Coronary Intervention at Centers With and Without On-Site Surgical Backup.
- Author
-
Joo Myung Lee, Doyeon Hwang, Jonghanne Park, Kyung-Jin Kim, Chul Ahn, and Bon-Kwon Koo
- Subjects
- *
CORONARY artery bypass , *MYOCARDIAL revascularization , *MYOCARDIAL infarction , *CORONARY disease , *SYSTEMATIC reviews , *META-analysis - Abstract
Background-Emergency coronary artery bypass grafting for unsuccessful percutaneous coronary intervention (PCI) is now rare. We aimed to evaluate the current safety and outcomes of primary PCI and nonprimary PCI at centers with and without on-site surgical backup. Methods and Results-We performed an updated systematic review and meta-analysis by using mixed-effects models. We included 23 high-quality studies that compared clinical outcomes and complication rates of 1 101 123 patients after PCI at centers with or without on-site surgery. For primary PCI for ST-segment-elevation myocardial infarction (133 574 patients), all-cause mortality (without on-site surgery versus with on-site surgery: observed rates, 4.8% versus 7.2%; pooled odds ratio [OR], 0.99; 95% confidence interval, 0.91-1.07; P=0.729; I2=3.4%) or emergency coronary artery bypass grafting rates (observed rates, 1.5% versus 2.4%; pooled OR, 0.76; 95% confidence interval, 0.56-1.01; P=0.062; I2=42.5%) did not differ by presence of on-site surgery. For nonprimary PCI (967 549 patients), all-cause mortality (observed rates, 1.6% versus 2.1%; pooled OR, 1.15; 95% confidence interval, 0.94-1.41; P=0.172; I2=67.5%) and emergency coronary artery bypass grafting rates (observed rates, 0.5% versus 0.8%; pooled OR, 1.14; 95% confidence interval, 0.62-2.13; P=0.669; I2=81.7%) were not significantly different. PCI complication rates (cardiogenic shock, stroke, aortic dissection, tamponade, recurrent infarction) also did not differ by on-site surgical capability. Cumulative meta-analysis of nonprimary PCI showed a temporal decrease of the effect size (OR) for all-cause mortality after 2007. Conclusions-Clinical outcomes and complication rates of PCI at centers without on-site surgery did not differ from those with on-site surgery, for both primary and nonprimary PCI. Temporal trends indicated improving clinical outcomes in nonprimary PCI at centers without on-site surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
43. Systematic Review of Patients Presenting With Suspected Myocardial Infarction and Nonobstructive Coronary Arteries.
- Author
-
Pasupathy, Sivabaskari, Air, Tracy, Dreyer, Rachel P., Tavella, Rosanna, and Beltrame, John F.
- Subjects
- *
MYOCARDIAL infarction , *CORONARY disease , *DISEASE prevalence , *MYOCARDIAL infarction risk factors , *HYPERLIPIDEMIA , *HYPERCOAGULATION disorders , *SYSTEMATIC reviews , *PATIENTS , *DISEASE risk factors , *PROGNOSIS - Abstract
Background—Myocardial infarction with nonobstructive coronary arteries (MINOCA) is a puzzling clinical entity with no previous evaluation of the literature. This systematic review aims to (1) quantify the prevalence, risk factors, and 12-month prognosis in patients with MINOCA, and (2) evaluate potential pathophysiological mechanisms underlying this disorder. Methods and Results—Quantitative assessment of 28 publications using a meta-analytic approach evaluated the prevalence, clinical features, and prognosis of MINOCA. The prevalence of MINOCA was 6% [95% confidence interval, 5%-7%] with a median patient age of 55 years (95% confidence interval, 51-59 years) and 40% women. However, in comparison with those with myocardial infarction associated with obstructive coronary artery disease, the patients with MINOCA were more likely to be younger and female but less likely to have hyperlipidemia, although other cardiovascular risk factors were similar. All-cause mortality at 12 months was lower in MINOCA (4.7%; 95% confidence interval, 2.6%-6.9%) compared with myocardial infarction associated with obstructive coronary artery disease (6.7%, 95% confidence interval, 4.3%-9.0%). Qualitative assessment of 46 publications evaluating the underlying pathophysiology responsible for MINOCA revealed the presence of a typical myocardial infarct on cardiac magnetic resonance imaging in only 24% of patients, with myocarditis occurring in 33% and no significant abnormality in 26%. Coronary artery spasm was inducible in 27% of MINOCA patients, and thrombophilia disorders were detected in 14%. Conclusions—MINOCA should be considered as a working diagnosis with multiple potential causes that require evaluation so that directed therapies may improve its guarded prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
44. Long-Term Clinical Outcome of Major Adverse Cardiac Events in Survivors of Infective Endocarditis.
- Author
-
Chia-Jen Shih, Hsi Chu, Pei-Wen Chao, Yi-Jung Lee, Shu-Chen Kuo, Szu-Yuan Li, Der-Cherng Tarng, Chih-Yu Yang, Wu-Chang Yang, Shuo-Ming Ou, and Yung-Tai Chen
- Subjects
- *
INFECTIVE endocarditis , *CARDIAC infections , *HEART failure , *MYOCARDIAL infarction , *STROKE ,HEART disease research - Abstract
Background--Substantial infective endocarditis (IE)-related morbidity and mortality may occur even after successful treatment. However, no previous study has explored long-term hard end points (ie, stroke, myocardial infarction, heart failure, cardiovascular death) in addition to all-cause mortality in IE survivors. Methods and Results--A nationwide population-based cohort study was conducted among IE survivors identified with the use of the Taiwan National Health Insurance Research Database during 2000 to 2009. IE survivors were defined as those who survived after discharge from first hospitalization with a diagnosis of IE. A total of 10 116 IE survivors were identified. IE survivors were matched to control subjects without IE at a 1:1 ratio through the use of propensity scores. The primary outcomes were stroke, myocardial infarction, readmission for heart failure, and sudden cardiac death or ventricular arrhythmia. The secondary outcomes were repeat IE and all-cause mortality. Compared with the matched cohort, IE survivors had higher risks of ischemic stroke (adjusted hazard ratio [aHR], 1.59; 95% confidence interval [CI], 1.40-1.80), hemorrhagic stroke (aHR, 2.37; 95% CI, 1.90-2.96), myocardial infarction (aHR, 1.44; 95% CI, 1.17-1.79), readmission for heart failure (aHR, 2.24; 95% CI, 2.05-2.43), sudden death or ventricular arrhythmia (aHR, 1.69; 95% CI, 1.44-1.98), and all-cause death (aHR, 2.27; 95% CI, 2.14-2.40). Risk factors for repeat IE were older age, male sex, drug abuse, and valvular replacement after an initial episode of IE. Conclusion--Despite treatment, the risk of long-term major adverse cardiac events was substantially increased in IE survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
45. Sedentary Behavior and Subclinical Cardiac Injury: Results From the Dallas Heart Study.
- Author
-
Harrington, Josephine L., Ayers, Colby, Berry, Jarett D., Omland, Torbjørn, Pandey, Ambarish, Seliger, Stephen L., Ballantyne, Christie M., Kulinski, Jacquelyn, deFilippi, Christopher R., and de Lemos, James A.
- Subjects
- *
MYOCARDIAL infarction , *SEDENTARY behavior , *CORONARY disease , *PHYSICAL activity , *MORTALITY - Abstract
The article discusses the sedentary behavior of chronic subclinical myocardial injury. Topics mention including the effects of a higher level of physical activity on troponin levels, association of increase sedentary time with increase cause of mortality and connection of chronic myocardial injury with increase sedentary time.
- Published
- 2017
- Full Text
- View/download PDF
46. ST--Segment-Elevation Myocardial Infarction Patients Randomized to a Pharmaco-Invasive Strategy or Primary Percutaneous Coronary Intervention.
- Author
-
Sinnaeve, Peter R., Armstrong, Paul W., Gershlick, Anthony H., Goldstein, Patrick, Wilcox, Robert, Lambert, Yves, Danays, Thierry, Soulat, Louis, Halvorsen, Sigrun, Ortiz, Fernando Rosell, Vandenberghe, Katleen, Regelin, Anne, Bluhmki, Erich, Bogaerts, Kris, and Van de Werf, Frans
- Subjects
- *
MYOCARDIAL infarction , *REPERFUSION , *MORTALITY , *SYMPTOMS , *CONGESTIVE heart failure , *PATIENTS - Abstract
Background--In the Strategic Reperfusion Early After Myocardial Infarction (STREAM) trial, a pharmaco-invasive (PI) strategy was compared with primary percutaneous coronary intervention (pPCI) in ST--segment-elevation myocardial infarction patients presenting within 3 hours after symptom onset but unable to undergo pPCI within 1 hour. At 30 days, the PI approach was associated with a nominally but nonstatistically significant lower incidence of the composite primary end point of death, shock, congestive heart failure, and reinfarction when compared with pPCI. The aim of the present study was to determine the effect of these strategies on 1-year mortality. Methods and Results--Vital status at 1 year was available in 936 of 944 (99.2%) and 941 of 948 (99.3%) patients in the PI and pPCI arm, respectively. At 1 year, all-cause mortality rates (6.7% versus 5.9%) were similar for PI and pPCI- treated patients (P=0.49; risk ratio, 1.13; 95% confidence interval, 0.79-1.62). Cardiac mortality rates were similar as well (4.0% versus 4.1%, P=0.93; risk ratio, 0.98; 95% confidence interval, 0.62-1.54). Overall, only 34 patients died between day 30 and 1 year, 20 in the PI arm and 14 in the pPCI arm, of whom 20 died of noncardiac reasons (13 in the PI and 7 in the pPCI arm). There was no significant difference in 1-year all-cause mortality between the 2 groups among the prespecified key subgroups. Conclusions--At 1 year, mortality rates in the PI and pPCI arms were similar in ST--segment-elevation myocardial infarction patients presenting within 3 hours after symptom onset and unable to undergo pPCI within 1 hour. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
47. Sex differences in long-term mortality after myocardial infarction: a systematic review.
- Author
-
Bucholz, Emily M, Butala, Neel M, Rathore, Saif S, Dreyer, Rachel P, Lansky, Alexandra J, and Krumholz, Harlan M
- Abstract
Background: Studies of sex differences in long-term mortality after acute myocardial infarction have reported mixed results. A systematic review is needed to characterize what is known about sex differences in long-term outcomes and to define gaps in knowledge.Methods and Results: We searched the Medline database from 1966 to December 2012 to identify all studies that provided sex-based comparisons of mortality after acute myocardial infarction. Only studies with at least 5 years of follow-up were reviewed. Of the 1877 identified abstracts, 52 studies met the inclusion criteria, of which 39 were included in this review. Most studies included fewer than one-third women. There was significant heterogeneity across studies in patient populations, methodology, and risk adjustment, which produced substantial variability in risk estimates. In general, most studies reported higher unadjusted mortality for women compared with men at both 5 and 10 years after acute myocardial infarction; however, many of the differences in mortality became attenuated after adjustment for age. Multivariable models varied between studies; however, most reported a further reduction in sex differences after adjustment for covariates other than age. Few studies examined sex-by-age interactions; however, several studies reported interactions between sex and treatment whereby women have similar mortality risk as men after revascularization.Conclusions: Sex differences in long-term mortality after acute myocardial infarction are largely explained by differences in age, comorbidities, and treatment use between women and men. Future research should aim to clarify how these differences in risk factors and presentation contribute to the sex gap in mortality. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
48. Discontinuation of Smokeless Tobacco and Mortality Risk After Myocardial Infarction.
- Author
-
Arefalk, Gabriel, Hambraeus, Kristina, Lind, Lars, Michaëlsson, Karl, Lindahl, Bertil, and Sundström, Johan
- Subjects
- *
MYOCARDIAL infarction , *SMOKELESS tobacco , *MORTALITY , *SMOKING cessation , *STATISTICAL hypothesis testing - Abstract
Background--Given the indications of increased risk for fatal myocardial infarction (MI) in people who use snus, a moist smokeless tobacco product, we hypothesized that discontinuation of snus use after an MI would reduce mortality risk. Methods and Results--All patients who were admitted to coronary care units for an MI in Sweden between 2005 and 2009 and were <75 years of age underwent a structured examination 2 months after discharge (the baseline of the present study). We investigated the risk of mortality in post-MI snus quitters (n=675) relative to post-MI continuing snus users (n=1799) using Cox proportional hazards analyses. During follow-up (mean 2.1 years), 83 participants died. The mortality rate was 9.7 (95% confidence interval, 5.7-16.3) per 1000 person-years at risk in post-MI snus quitters and 18.7 (14.8-23.6) per 1000 person-years at risk in post-MI continuing snus users. After adjustment for age and sex, post-MI snus quitters had half the mortality risk of post-MI continuing snus users (hazard ratio, 0.51; 95% confidence interval, 0.29-0.91). In a multivariable-adjusted model, the hazard ratio was 0.57 (95% confidence interval, 0.32-1.02). The corresponding estimate for people who quit smoking after MI versus post-MI continuing smokers was 0.54 (95% confidence interval, 0.42-0.69). Conclusions--In this study, discontinuation of snus use after an MI was associated with a nearly halved mortality risk, similar to the benefit associated with smoking cessation. These observations suggest that the use of snus after MI should be discouraged. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
49. Mortality among high-risk patients with acute myocardial infarction admitted to U.S. teaching-intensive hospitals in July: a retrospective observational study.
- Author
-
Jena, Anupam B, Sun, Eric C, and Romley, John A
- Abstract
Background: Studies of whether inpatient mortality in US teaching hospitals rises in July as a result of organizational disruption and relative inexperience of new physicians (July effect) find small and mixed results, perhaps because study populations primarily include low-risk inpatients whose mortality outcomes are unlikely to exhibit a July effect.Methods and Results: Using the US Nationwide Inpatient sample, we estimated difference-in-difference models of mortality, percutaneous coronary intervention rates, and bleeding complication rates, for high- and low-risk patients with acute myocardial infarction admitted to 98 teaching-intensive and 1353 non-teaching-intensive hospitals during May and July 2002 to 2008. Among patients in the top quartile of predicted acute myocardial infarction mortality (high risk), adjusted mortality was lower in May than July in teaching-intensive hospitals (18.8% in May, 22.7% in July, P<0.01), but similar in non-teaching-intensive hospitals (22.5% in May, 22.8% in July, P=0.70). Among patients in the lowest three quartiles of predicted acute myocardial infarction mortality (low risk), adjusted mortality was similar in May and July in both teaching-intensive hospitals (2.1% in May, 1.9% in July, P=0.45) and non-teaching-intensive hospitals (2.7% in May, 2.8% in July, P=0.21). Differences in percutaneous coronary intervention and bleeding complication rates could not explain the observed July mortality effect among high risk patients.Conclusions: High-risk acute myocardial infarction patients experience similar mortality in teaching- and non-teaching-intensive hospitals in July, but lower mortality in teaching-intensive hospitals in May. Low-risk patients experience no such July effect in teaching-intensive hospitals. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
50. National trends in heart failure hospitalization after acute myocardial infarction for Medicare beneficiaries: 1998-2010.
- Author
-
Chen, Jersey, Hsieh, Angela Fu-Chi, Dharmarajan, Kumar, Masoudi, Frederick A, and Krumholz, Harlan M
- Abstract
Background: Previous studies have reported conflicting findings regarding how the incidence of heart failure (HF) after acute myocardial infarction (AMI) has changed over time, and data on contemporary national trends are sparse.Methods and Results: Using a complete national sample of 2 789 943 AMI hospitalizations of Medicare fee-for-service beneficiaries from 1998 through 2010, we evaluated annual changes in the incidence of subsequent HF hospitalization and mortality using Poisson and survival analysis models. The number of patients hospitalized for HF within 1 year after AMI declined modestly from 16.1 per 100 person-years in 1998 to 14.2 per 100 person years in 2010 (P<0.001). After adjusting for demographic factors, a relative 14.6% decline for HF hospitalizations after AMI was observed over the study period (incidence risk ratio, 0.854; 95% confidence interval, 0.809-0.901). Unadjusted 1-year mortality following HF hospitalization after AMI was 44.4% in 1998, which decreased to 43.2% in 2004 to 2005, but then increased to 45.5% by 2010. After adjusting for demographic factors and clinical comorbidities, this represented a 2.4% relative annual decline (hazard ratio, 0.976; 95% confidence interval, 0.974-0.978) from 1998 to 2007, but a 5.1% relative annual increase from 2007 to 2010 (hazard ratio, 1.051; 95% confidence interval, 1.039-1.064).Conclusions: In a national sample of Medicare beneficiaries, HF hospitalization after AMI decreased from 1998 to 2010, which may indicate improvements in the management of AMI. In contrast, survival after HF following AMI remains poor, and has worsened from 2007 to 2010, demonstrating that challenges still remain for the treatment of this high-risk condition after AMI. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.